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Résumé  
 
La leucémie lymphoblastique aiguë (LLA) représente environ 25% des cancers pédiatriques 
diagnostiqués chaque année. Dans 80 % des cas, une rémission complète est observée. 
Cependant, les patients résistants aux traitements ainsi que les patients en rechute présentent 
un mauvais pronostique. Les altérations épigénétiques sont des facteurs essentiels dans le 
développement et la progression de la maladie, ainsi qu’à la résistance aux traitements. Lors 
d’un criblage de médicaments  approuvés par la FDA, nous avons découvert des molécules 
ayant des caractéristiques anticancéreux et épigénétiques. Pour évaluer l’activité de ces 
molécules, nous avons procédé à un criblage secondaire sur plusieurs lignées cellulaires 
leucémiques. Nous avons découvert qu’une de ces molécules, un glucoside cardiotonique 
appelé la proscillaridine A, avait une activité anticancéreuse spécifique pour des cellules 
leucémiques. Nous faisons donc l’hypothèse que la proscillaridine A pourrait avoir des effets 
épigénétiques et anticancéreux dans des modèles précliniques de LLA. Pour tester cette 
hypothèse, nous avons traité deux lignées cellulaires de LLA Nalm-6 (LLA pre-B) et Molt-4 
(T-LLA) in vitro pendant 2 à 96 heures à des doses pertinentes sur le plan clinique. Nous 
avons alors pu observer une inhibition de croissance qui était dépendante de la dose 
administrée dans les deux lignées cellulaires, avec des valeurs de 50% d’inhibition de 
croissance (CI50) de 3.0 nM pour les Nalm-6 et de et 2.3 nM pour les Molt-4. De plus, nos 
études sur le cycle cellulaire par BrdU démontrent un arrêt en phase G2/M. Nous avons 
également détecté par immunobuvardage de type western des baisses significatives de 
l’acétylation de résidus de l’histone 3. Les niveaux d’expression des enzymes responsables de 
cette acétylation, les histones acétyltransférases CBP, P300 et TIP60 ainsi que de l’oncogène 
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C-MYC étaient  également diminuées. Par des analyses de séquençage de l’ARN, nous avons 
observé une augmentation de l’expression des gènes impliquées dans les processus d’apoptose 
et de différentiation cellulaire, ainsi qu’une diminution des gènes impliqués dans la 
prolifération cellulaire comme en particulier les gènes cibles de C-MYC. Ces résultats 
prometteurs suggèrent le potentiel prometteur de la proscillaridine A comme nouvelle thérapie 
pour les patients atteints de LLA. 
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Abstract 
 
Acute lymphoblastic leukemia (ALL) represents approximately 25% of all pediatric cancers 
diagnosed every year. In about 80% of cases, pediatric patients will attain a 5-year event-free 
survival. Unfortunately, patients who are resistant to treatment or who relapse have a poor 
prognosis. Hence, novel therapeutic approaches are necessary to increase survival rates. 
Epigenetic alterations, such as DNA methylation and histone modifications, are involved in 
disease development, progression, and in particular, resistance to treatment. These reversible 
alterations represent novel targets in ALL. We recently discovered candidate epigenetic drugs 
in FDA-approved drug libraries. We performed a secondary screen to test the activity of these 
drugs in a panel of cancer cell lines. We found that a cardiac glycoside, called proscillaridin A, 
had anticancer specificity against pediatric leukemia cell lines. Thus, we hypothesize that 
proscillaridin A has some drug repositioning potential in pediatric ALL. To characterize its 
epigenetic mechanism of action, we treated two ALL cell lines Nalm-6 (pre-B ALL) and 
Molt-4 (T-ALL) in vitro for different time points (2-96h) with clinically relevant 
concentrations of proscillaridin A and analyzed cell growth, cell cycle, gene expression and 
chromatin modifications. We observed dose-dependent growth inhibition in both cell lines, 
where 50% of growth inhibition (IC50) was obtained at 3.0 and 2.3 nM in Nalm-6 and Molt-4, 
respectively. Our results using BrdU staining indicate a cell cycle block in the G2/M phase. 
By western blot, we detected significant decreases in histone 3 acetylation levels (H3K14ac, 
H3K9ac, and H3K27ac). Decreases in histone acetylation were associated with a significant 
reduction in histone acetyltransferase expression (CBP, P300 and TIP60) as well as the C-
MYC oncogene. By RNA sequencing and gene set enrichment analysis, we observed an 
upregulation of apoptosis and cell differentiation genes, as well as a decrease in cell 
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proliferation and C-MYC target genes. These promising results illustrate the potential of using 
the cardiac glycoside proscillaridin A as a novel drug in treatment of relapsed or refractory 
ALL. 
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 Chapter 1: Introduction 
1.0 Leukemia 
 
 
 Leukemia is a malignant disease affecting normal developmental and maturation 
processes of white blood cells and lymphocytes [1, 2]. It is described as a progressive loss in 
normal cell maturation and an increase in cell proliferation, leading to abnormally high levels 
of undifferentiated cells in the bone marrow and blood stream [1, 2]. The accumulation of 
undifferentiated white blood cells and lymphocytes also disrupts the bone marrow niche, and 
consequently affects the maturation and production of other hematopoietic progenitor cells [1-
3].  
 Depending on the blood cell affected, leukemia is separated into two major groups: 
lymphoblastic and myeloid. Whereas lymphoblastic leukemia only affects T- or B-
lymphocytes, referred to as T-ALL or B-ALL, respectively, myeloid leukemia affects all other 
white blood cells, such as basophils, neutrophils, eosinophils, and monocytes [2]. Leukemia 
can also be classified as being either acute or chronic, depending on the maturity of the cell 
affected and the rate of disease progression. In cases of acute leukemia, patients are diagnosed 
with a rapidly progressing disease [2]. On the other hand, patients diagnosed with chronic 
leukemia are portrayed as having a slower rate of disease development and progression [2]. 
There are four main classes of leukemia: chronic lymphoblastic leukemia (CLL), chronic 
myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia 
(AML) [2, 4].  
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 Pathophysiology of each leukemia subtype varies drastically from one main class to 
another [2, 4]. Hence, each leukemia subtype will have different biological characteristics and 
some will be more prevalent in certain age groups compared to others [2]. For instance, CLL 
is most frequently observed in elderly patients and affects cells in the bone marrow 
compartment and blood stream [2]. Patients can either be diagnosed with an aggressive or a 
dormant form of CLL, the former requiring therapeutic intervention while the latter does not 
[2]. Differences in cell biology, such as cell surface markers and chromosomal aberrations, 
can help classify patients in either the dormant or aggressive CLL categories [2]. In addition, 
presence of certain mutations or disorders in important tumor suppressor genes – like p53 for 
instance – are linked to the aggressive CLL subtype and result in a poor prognosis [2, 5].  
 On the other hand, CML only affects myeloid cell development in the bone marrow, 
which eventually leads to higher concentrations of undifferentiated myeloid cells in the blood 
stream [2]. Peak incidence for CML patients is observed between 50 and 60 years of age [2]. 
The most common chromosomal aberration involved in development of CML is a 
translocation between chromosomes 9 and 22, also known as the Philadelphia chromosome, 
forming the BCR-ABL fusion gene [2, 6, 7]. This translocation is observed in approximately 
90% of CML patients [2, 6, 7]. There are three main phases in CML that correlate to disease 
progression and influence prognosis as well as overall survival: a chronic, an intermediate, and 
a blastic phase [2, 8]. As disease progresses from the chronic phase to the intermediate and 
blastic phases, there are increasing numbers of immature white blood cells in the bone marrow 
and blood stream [8]. Eventually, patients are placed into the blastic phase category upon the 
occurrence of white blood cell infiltration into different organs or greater than 30% blast 
 3 
counts in their blood stream or bone marrow [8]. The blastic phase is deadly in most cases, 
usually leading to patients succumbing from their disease within 6 months [2, 8].  
 Alternatively, ALL is a malignant blood disorder affecting solely T- and B- 
lymphocytes [2, 9, 10]. ALL essentially alters development of T- and B- cells by inducing an 
increase in the cell proliferation and survival pathways [2, 10]. Interestingly, ALL is very 
rarely diagnosed in adults but has very high prevalence in children [2]. Like chronic leukemia 
subtypes, ALL is associated with numerous chromosomal translocations leading to formation 
of fusion proteins playing critical roles in disease initiation and progression by affecting 
important cellular pathways [2, 9, 11].  
 Like the other leukemia subtypes, AML is described as having an interruption in cell 
differentiation leading to accumulations of AML blast cells in the bone marrow that will 
eventually spill into the blood stream [2, 11]. AML is a disease affecting primarily adults, but 
in rare cases affects children as well [2, 11]. Pediatric cases of AML are associated with many 
chromosomal abnormalities, the most common one being translocations encompassing the 
mixed lineage leukemia (MLL) protein [2, 11]. 
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Figure 1: Normal and abnormal hematopoiesis.  
Differentiation of hematopoietic stem cells into either the myeloid or lymphoid lineages. Cells 
affected in myeloid and lymphoblastic leukemia are myeloblasts and lymphoblasts, 
respectively. HSC: hematopoietic stem cell, MSC: myeloid stem cell, LSC: lymphoid stem 
cell, Ne: neutrophil, Mo: monocyte, Eo: eosinophil, Ba: basophil. [12] 
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 2.0 Pediatric Leukemia 
  
 Leukemia is the most common pediatric cancer diagnosed every year, representing 
approximately 30% of all newly diagnosed cases in pediatric patients around the world [11]. 
The two most common leukemia subtypes diagnosed in pediatric patients are ALL and AML 
[11]. Approximately 85% and 15% of acute leukemia cases in children are ALL and AML, 
respectively [13, 14].  
The following sections describe the biology behind pediatric ALL and AML development and 
current treatment methods for each leukemia subtype. 
 
Figure 2: Bone marrow accumulation of lymphoblasts in a pediatric ALL patient. 
In patients with ALL, there is an accumulation of leukemic blasts in the bone marrow, which 
disrupts development of other blood cells. Leukemic blasts are described as having very large 
nuclei, as shown by the black arrows.  
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2.1 Pediatric ALL, Current Treatments, and Relapse 
 
2.1.1 Biology of ALL 
  
 Acute lymphoblastic leukemia (ALL) is characterized as a blood malignancy that 
induces a decrease in differentiation and an increase in proliferation in lymphoid progenitor 
cells [15, 16]. These events lead to an overpopulation of the bone marrow compartment and 
blood stream with immature leukemic cells, also called “blasts”. As a consequence, 
accumulation of blast cells affects normal blood cell development and impairs hematopoiesis 
[15, 16]. Depending on the lymphoid progenitor affected, ALL can be subdivided into two 
main categories: B- and T-ALL, the most common form in children being B-ALL [16, 17]. 
ALL accounts for approximately 25% of all pediatric cancers diagnosed every year with 
incidence peaking in children between the ages of 2 and 5 [18, 19]. Although current treatment 
methods cure over 85% of pediatric patients diagnosed with ALL in developed countries 
worldwide, patients who either relapse or experience resistance to treatment have a very poor 
outcome portrayed by an overall survival of approximately 25% [10, 20]. Hence, because of 
its prevalence, ALL is the leading cause of death by disease in children.  
 Molecular mechanisms underlying B- and T-ALL include inactivation of tumor 
suppressor genes and irregular activation of oncogenes and signal transduction pathways [21-
23]. These genetic aberrations affect key regulatory processes, producing highly proliferative 
blast cells with unlimited self-renewal and cell-survival properties [21-23]. Chromosomal 
lesions, such as abnormal chromosomal numbers and structural abnormalities – especially 
translocations – are often identified in the pediatric ALL population [21-23]. Evidently, these 
chromosomal lesions differ between the two ALL subtypes.  
 7 
 The most common chromosomal translocation observed in pediatric B-ALL is the 
translocation between ETS variant 6 (ETV6), located on chromosome 12, and Runt-related 
transcription factor 1 (RUNX1), located on chromosome 21, termed the ETV6-RUNX1 fusion 
protein [24]. This translocation accounts for roughly 25% of all pediatric B-ALL cases [24]. In 
normal cells, both proteins act as transcription factors required in hematopoiesis and normal 
cell differentiation [24]. Fortunately, patients with the ETV6-RUNX1 translocation have an 
elevated survival rate [25]. The TCF3-PBX1 fusion protein, made up transcription factor 3 
(TCF3) and pre-B cell leukemia homeobox 1 (PBX1), accounts for approximately 5% of B-
ALL cases, and is associated with a good prognosis, despite the slight risk in CNS relapse 
[26]. For this reason, patients diagnosed with TCF3-PBX1 leukemia are given higher doses of 
CNS preventative therapies [26]. Next, translocations involved in forming the BCR-ABL1 
fusion protein, formed from the fusion between breakpoint cluster region protein (BCR) and 
Abelson murine leukemia viral oncogene homolog 1 (ABL1), account for about 3% of cases 
and are correlated with good patient outcomes due to the recent introduction of imatinib in 
their treatment regimens [27]. Finally, translocations involving the mixed lineage leukemia 
(MLL) protein, which occur at a much higher frequency in patients under two years old, 
account for about 5% of B-ALL cases [19, 24, 28].  
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Figure 3: Pediatric B-ALL subtypes. 
Pie chart of pediatric B-ALL subtypes.  
 
 Chromosomal translocations in T-ALL are not as well characterized as their B-ALL 
counterparts. Pediatric patients are classified into four categories, each of which is associated 
with upregulation of different oncogenes [24, 29]. The four major oncogenes present in T-
ALL are HOX11, LYL1, TAL-LMO2, and HOX3 [24, 29]. Translocations between the T-cell 
receptor and the HOX11 oncogene represent a distinct subset of patients part of the HOX11 
category. Other than these noticeable chromosomal translocations, T-ALL can also be 
illustrated by abnormal NOTCH1 signaling that impairs T-cell differentiation in 
approximately half of T-ALL cases [30].  
 
Hyperdiploidy	  ETV6-­‐RUNX1	  Trisomy	  4	  and	  10	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Figure 4: Pediatric T-ALL subtypes. 
Pie chart of the four major oncogene subtypes in pediatric T-ALL.   
  
 In addition, chromosomal and genetic alterations also take part in development of 
acute leukemia in children. For example, Down’s syndrome (trisomy 21) increases the risk to 
develop pediatric ALL or AML significantly [31]. Patients with Down syndrome are 
frequently associated with ETV6-RUNX1 chromosomal translocation and are often 
categorized as high-risk mostly because of frequent relapse rates and lower overall survival 
[32].  
 Gain or loss of entire chromosomes, termed hyperdiploidy and hypodiploidy, 
respectively, are also frequently observed in pediatric patients [19, 24]. Chromosomes X, 4, 6, 
10, 14, 17, 18, and 21 are the ones most often gained in ALL patients with hyperdiploidy and 
make up approximately 30% of all cases [19, 27]. These patients are associated with positive 
outcome [27]. Hypodiploidy, on the other hand, is much less frequent, observed in 
approximately 1% of patients, and is correlated to a poor prognosis [27]. 
60%	  10%	  
20%	  
10%	   TAL/LMO	  
HOX11	  (TLX1)	  
HOX11L2/TLX3	  LYL1	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2.1.2 Treatment of pediatric ALL  
 
 Because ALL is such a diverse disease, the diagnostic of the correct subtype is critical 
in determining which treatment methods a patient should undergo and whether or not a given 
treatment will fail [33]. Hence, at the time of diagnosis, risk stratification for a patient is 
established and is an important aspect in attaining overall survival [33, 34]. Therefore, prior to 
starting treatment, patients are labeled as standard, intermediary, or high-risk [11]. Two 
important clinical characteristics considered at the time of diagnosis are age and white blood 
cell count [11, 33-35]. Favorable outcomes are observed in patients between the ages of 1 and 
10, whereas unfavorable outcomes are observed in patients under 1 year of age and older than 
10 years of age [33]. Also, white blood cell counts greater than 50,000 cells per µL of blood 
are predicted to have an unfavorable outcome [33].  
 Another important characteristic examined is leukemic cell penetration into sanctuary 
sites, defined as areas in the body that are difficult to target with conventional chemotherapy. 
Two common sanctuary sites in leukemia are the central nervous system (CNS) and testis [11, 
33]. Penetration of leukemic cells into these organs is correlated with an unfavorable outcome 
and is usually involved in patient relapse [11, 33].  
 After establishing risk stratification, patients undergo treatment according to their risk 
category [11, 33]. Generally speaking, current treatment methods include three main stages 
[11, 33]. The first step in ALL treatment is induction therapy, lasting between 4-6 weeks; the 
goal of induction therapy is to eliminate all leukemic blasts from the bone marrow [11, 33]. 
Four medications are used in induction therapy: vincristine, prednisone, L-asparaginase, and 
an anthracycline (either doxorubicin or daunorubicin) [11, 33]. The usual two-drug regimen 
consists of vincristine followed by prednisone, which leads to remission in about 85% of 
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patients [11]. Addition of a third drug – either L-asparaginase or an anthracycline – further 
increases the remission rate to approximately 95% [11]. In high-risk patients, a fourth drug, 
usually an anthracycline or methotrexate, is added to the regimen in order to attain remission 
[11].  
 Since ALL penetration into the CNS is correlated with increased rates of patient 
relapse, CNS preventative therapy has also been established in treating the disease [11]. CNS 
preventative therapy includes intrathecal methotrexate injections followed by low to moderate 
cranial irradiation to eliminate any leukemic cell that crossed the blood-brain barrier [11]. 
CNS preventative therapy is very efficient, and leads to good prognosis in a majority of cases 
with minimal cytotoxicity if started at the same time as chemotherapy regimens [11, 36]. 
Unfortunately, some patients develop secondary cancers due to side effects of treatment, such 
as non-Hodgkin lymphoma and cancers affecting the brain and thyroid organs [37].  
 Induction therapy is followed by the second phase in ALL treatment called 
consolidation therapy. The goal of consolidation therapy is to eliminate any remaining 
leukemic cell population from the patient’s bone marrow and blood stream in order to prevent 
any further disease progression or relapse [11, 33]. Treatment protocols differ in length and 
intensity, usually lasting 6-9 months, but can last longer if a patient is in the high-risk category 
[33]. During this phase, patients receive higher doses of drugs formerly used in induction 
chemotherapy. Different classes of cytotoxic drugs not previously used during induction 
therapy, such as mercaptopurine, etoposide, cyclophosphamide and cytarabine, can also be 
added to treatment regimens in order to prevent resistance [11, 33].  
 The third and final stage of ALL treatment is maintenance therapy, where patients 
receive low-dose of chemotherapy drugs for approximately 2-3 years in order to prevent 
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disease relapse [11, 33]. During this phase, treatment protocols include weekly methotrexate 
and mercaptopurine administrations, in addition to prednisone and vincristine on a monthly 
basis [11, 33].  
  
2.1.3 Personalized Treatments for ALL 
 
 Nowadays, personalized approaches exist taking patient risk stratification into account. 
Depending on chromosomal aberration identified in ALL patients, treatments can be 
administered to specifically target cancer cells with minimal effects on healthy cells. Several 
classes of these targeted therapies exist for ALL, with a few of these currently undergoing 
clinical trials [9, 27, 34, 38].  
 First, monoclonal antibodies can be used in treating specific ALL cases having cell 
surface receptors or markers that can potentially be targeted [9, 38]. A monoclonal antibody 
can either be conjugated or unconjugated; the former being attached to a radioactive or 
cytotoxic compound whereas the latter is not [9, 38]. An unconjugated monoclonal antibody 
identifies a target on the surface of the cell and initiates either antibody-dependent cell 
mediated toxicity or complement-dependent cytotoxicity [9]. On the other hand, conjugated 
monoclonal antibodies identify and bind onto their target cell and get internalized along with 
their conjugate. This phenomenon enables the release of the cytotoxic compound into the cell, 
causing cell death [38]. Numerous examples using unconjugated monoclonal antibodies exist 
in treating ALL. For instance, rituximab, a chimeric murine and human monoclonal antibody, 
specifically targets CD20 surface antigen present on B-lymphocytes enabling its use as a 
target in B-ALL cases [38]. CD20 expression is observed in over 50% of pediatric B-ALL 
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cases, and is usually upregulated after chemotherapy treatment [9, 39, 40]. The monoclonal 
antibody alemtuzumab specifically targets CD52 surface antigen present on T- and B-ALL 
cells and can be used in relapsed or refractory cases of pediatric ALL [9, 38]. Although 
response rates for alemtuzumab are generally very low, patients with the t(12;21) translocation 
have a slightly higher sensitivity to treatment compared to patients without this translocation 
[9, 41]. Another popular monoclonal antibody is epratuzumab. Epratuzumab targets CD22 
surface antigen present primarily on pre-B cells, and can therefore be used in treating pediatric 
pre-B ALL [9, 38]. Recent studies suggest it also has promising effects on relapsed B-ALL 
cases in combination with chemotherapy, inducing a complete response in the majority of 
cases [9, 38, 42, 43].  
 Compared to unconjugated monoclonal antibodies, conjugated monoclonal antibodies 
appear to be more efficient in treating pediatric ALL [38]. Inotuzumab ozogamicin is a 
monoclonal antibody attached to calicheamicin, an anti-tumor antibiotic showing promising 
results in preliminary tests on patients with refractory ALL [38, 44]. Its mode of action 
specifically targets CD22-positive cells, which incorporate calicheamicin leading to cellular 
toxicity [38]. Additionally, SAR3419 is a monoclonal antibody linked to the natural cytotoxic 
compound dregeanin DM4 [45]. SAR3419 is used to target CD19, a cell surface marker 
expressed on all immature B-lymphocytes and can therefore be used in treating pediatric B-
ALL cases [9, 45]. It was also recently identified as having synergistic effects when 
administered in combination with chemotherapy drugs presently used in induction therapy in 
pediatric ALL [46].  
 Second, another important group of compounds used in targeted ALL treatments are 
tyrosine kinase inhibitors. Because constitutive expression of tyrosine kinase inhibitors plays 
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an important role in development of leukemia and eventually resistance to treatment, targeting 
these receptors is a great way to also target development and progression of the disease [9, 
34]. Specific molecules can target the two major groups of tyrosine kinase receptors in 
pediatric ALL: the BCR-ABL (in Philadelphia positive ALL, referred to Ph+ ALL) and the 
FLT3 tyrosine kinases [9, 34].  
 The recent discovery and approval of imatinib in 2013, a BCR-ABL tyrosine kinase 
inhibitor, greatly changed the overall long-term survival of pediatric patients with Ph+ 
leukemia from approximately 40% to 85% [9, 47]. In fact, when administered with 
conventional chemotherapy, patients treated with imatinib had similar long-term survival as 
patients undergoing hematopoietic stem cell transplantation [48]. Unfortunately, like many 
other types of treatments for pediatric ALL, resistance to treatment develops [49, 50]. 
Although very rare in children, point mutations of the ABL domain appear to be one of the 
leading causes of resistance to treatment and eventually causing death of the patient [9, 34, 49, 
51]. After discovery of imatinib, development and approval of dasatinib and ponatinib, second 
and third generation BCR-ABL tyrosine kinase inhibitors respectively, quickly went underway 
in order to counter the resistant ALL cases [34, 51-53]. These two drugs show promising 
results in recent clinical trials on targeting BCR-ABL resistant cells. In addition to being more 
effective against Ph+ ALL, they are more efficient at crossing the blood-brain barrier and 
targeting leukemic cells in the central nervous system to prevent any potential relapse [9, 54].  
 FMS-like tyrosine kinase 3 – also known as FLT3 – is a tyrosine kinase receptor 
usually present in CD34+ pre-B progenitor cells that is essential in normal hematopoiesis [9, 
34, 55]. However, when abnormally expressed by activating mutations, FLT3 upregulates 
proliferation pathways leading to B-ALL development [9, 34]. Although FLT3 gain-of-
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function mutations are rare in pediatric ALL cases, therapies targeting mutant forms of the 
protein consist mainly of lestaurtinib in combination with chemotherapy are administered to 
patients diagnosed with FLT3-driven ALL [9, 56]. Although this combination has shown 
promising results in certain cases, it still needs to be improved in order to attain better 
complete response rates on a regular basis [9].  
 Third, drugs that target nucleic acid synthesis are also used in treating certain cases of 
pediatric ALL. Initially, this drug family was rarely used in treating pediatric ALL since they 
are not specific and extremely toxic, but recent improvements have enabled use of these 
compounds in either high-risk or relapse cases [9, 57]. Clofarabine, a molecule inhibiting 
DNA polymerase and DNA repair among other things, is sometimes used in combination with 
conventional chemotherapy in relapse or resistant cases [58]. In other instances, clofarabine is 
used as a monotherapy in patients that already received high doses of cytotoxic therapy [59-
61]. More recently, the Children’s Oncology Group (COG) is evaluating clofarabine 
administration in combination with drugs used during induction therapy for high-risk pediatric 
ALL patients [9]. Another compound in this category is the prodrug nelarabine; once it enters 
a cell, it is metabolized to a nucleoside analog and rapidly gets phosphorylated [9]. It is then 
inserted into the DNA sequence, prevents DNA synthesis, and induces apoptosis [9, 62]. 
Interestingly, since nelarabine is more potent in T-cell malignancies compared to B-cell 
malignancies, it is more often used on T-ALL patients who either relapse or are unresponsive 
to treatment [9, 63]. It is currently undergoing a clinical trial on a potential addition in 
induction therapy for pediatric T-ALL cases [9].   
 Fourth, compounds that inhibit serine and threonine kinases, responsible for irregular 
growth pathways, are also used in targeted therapy against pediatric ALL. Overexpression of 
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the serine/threonine kinases leads to cell proliferation and development of leukemia [9]. There 
are several types of serine/threonine kinases that can potentially be targeted for therapy in 
pediatric ALL [9, 34]. First, the Janus kinase (JAK) family of tyrosine kinases are great targets 
in high-risk pediatric ALL patients in which the JAK-STAT pathway is aberrantly expressed 
[9, 34]. The JAK pathway is usually overexpressed in high-risk B-ALL patients, as well as in 
children with ALL and Down syndrome [9, 34, 64]. Unfortunately, not much is known about 
the efficacy of JAK-STAT inhibition in pediatric ALL since clinical trials are currently 
underway [9, 34].  
 Another type of serine/threonine kinase that is studied in pediatric ALL cases is the 
mammalian target of rapamycin (mTOR). Aberrant activation of the PI3K/Akt/mTOR 
pathway is involved in accelerated cell growth and proliferation, which leads to development 
of leukemia [9, 34, 65]. Hence, targeting the mTOR pathway using mTOR inhibitors is an 
efficient way to target ALL with a hyperactive mTOR signaling pathway. In recent years, 
preclinical and clinical studies have determined a synergistic effect between mTOR inhibitors 
and chemotherapy drugs used in induction and maintenance therapies, such as 
cyclophosphamide, methotrexate, doxorubicin, etoposide, asparaginase, prednisone, and 
vincristine [66-70]. Several mTOR inhibitors exist in treating pediatric ALL. mTOR 
inhibitors, such as rapamycin or any of its analogs, have been greatly studied in vitro on ALL 
cell lines – especially pre-B ALL – and seem to have positive effects [34, 71]. In addition, 
combination studies in Ph+ leukemic cell lines demonstrate synergistic effects when 
rapamycin is combined with daunorubicin in vitro [72]. Not only did the combinational 
approach demonstrate a higher cytotoxicity in these cell lines, but it also increased autophagy 
and blockage of the cell cycle when compared to daunorubicin monotherapy [72]. 
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Development of steroid resistance in pediatric ALL patients is one of the leading causes of 
treatment failure [68]. Interestingly, rapamycin treatment can actually sensitize steroid-
resistant cells, which can potentially lead to countering steroid-related resistance [68]. These 
preclinical results provided a rationale to pursue clinical trials in pediatric ALL patients. 
Hence, ongoing clinical trials in combining rapamycin or its analog temsirolimus with 
cytotoxic compounds have been studied in relapsed or resistance pediatric ALL 
(NCT01403415) [73].   
 Fifth, targeting a cancer cell’s survival ability is another suitable approach for 
chemotherapy. In normal cells, there is a balance between apoptosis and cell survival 
mechanisms. In cancer cells, however, the balance is shifted towards an interruption of the 
apoptotic pathways and upregulation of survival genes and their downstream effectors [9].   
Since there are many genes involved in pro-survival mechanisms in leukemic cells, several 
agents can be administered to patients depending on their gene expression profiles [9, 34]. 
Bortezomib, a proteasome inhibitor, prevents ubiquitin-dependent proteasome degradation, 
which subsequently inhibits the action of NF-κB and activates pro-apoptotic and cell cycle 
regulators such as p53, p21, p27, and Bax [9, 34]. The overall effect of bortezomib treatment 
is to increase effects of chemotherapy drugs by lowering the apoptosis threshold of leukemic 
cells [9, 34, 74-76]. Treatment of ALL cell lines with bortezomib has shown positive effects, 
prompting its use in numerous clinical trials in pediatric ALL patients [77]. As a monotherapy, 
bortezomib has been shown to be inefficient. As demonstrated in a phase I combination 
clinical trial with reinduction chemotherapy drugs, it has very promising effects in resistant 
pediatric ALL [9, 34, 78, 79]. The subsequent phase II part of this trial further demonstrated 
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positive effects of bortezomib combination with reinduction cytotoxic treatment in both B- 
and T-ALL resistant patients [34, 79].    
 Another pro-survival target in pediatric ALL are heat shock proteins (HSPs) – more 
specifically Hsp90. These proteins are involved with leukemia cell formation by trafficking 
and stabilizing oncogenes required in development of a malignant proliferative phenotype 
with abnormal survival properties [9, 80, 81]. In addition, elevated amounts of Hsp90 in 
patients are correlated with poor prognosis; hence, targeting these proteins in high-risk cases 
can potentially increase overall survival [81]. In preclinical studies, tanespimycin, an Hsp90 
inhibitor, repressed growth of ALL cells in vitro and has even been shown to synergize with 
imatinib in Ph+ ALL cell lines [9, 82]. More recently, Akahane and colleagues demonstrated 
that NVP-AUY922, a much stronger inhibitor for the Hsp90 protein, promotes apoptosis in T-
ALL cells [83]. This product is already in clinical trials for solid tumors and can potentially be 
an interesting candidate drug in treating T-ALL pediatric patients [84]. Despite recent 
advances in Hsp90 inhibitor development, these drugs are not frequently used in clinic since a 
therapeutic window has not yet been established [83, 85].  
 Other anti-apoptotic proteins frequently overexpressed in pre-B-ALL and T-ALL are 
members of the Bcl-2 family. Not only are these proteins important in regulating apoptosis, 
but they also play key roles in resistance to treatment during induction therapy [86]. 
Development of navitoclax and obatoclax, two Bcl-2 family inhibitors, was necessary in order 
to treat patients with highly resistant forms of ALL [87]. Both inhibitors show promising 
effects in vitro on pediatric ALL cell lines in addition to clinical studies on adult patients 
suffering from ALL and AML [88-91]. However, clinical trials have yet to be conducted on 
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pediatric patients [88-91]. Thus far, preclinical anti-Bcl-2 therapy has been shown to be more 
effective on t(4;11) ALL cell lines compared to all other forms of the disease [92].  
  
2.2.4 Relapsed and Resistant pediatric ALL 
 
 While the majority of pediatric ALL patients are cured with current chemotherapy 
regimens, approximately 20% experience a relapse, with boys relapsing more frequently than 
girls [9, 11, 34]. Research on relapsed ALL patients has identified leukemic blast populations 
that have acquired chromosomal aberrations and genetic mutations, making them more 
resistant to chemotherapy treatment compared to blasts isolated at initial diagnosis [93-98]. 
Furthermore, genomic studies on blast cells present at relapse have determined an 
overexpression of the DNA repair and cell survival gene pathways compared to blasts at 
diagnosis [93, 99].  
 ALL relapse is primarily caused by expansion of a clonal population leading to 
treatment resistance [93]. Recent studies on ALL relapse have concluded it is a clonal disease. 
In fact, studies by Mullighan and colleagues have determined that cells present at relapse are 
also present at initial diagnosis at a very low concentration. This cell population then 
undergoes clonal expansion, populate the bone marrow and sanctuary sites in the body, and 
drive disease relapse [93, 95].  
 There are many factors that determine how clonal expansion affects the development 
of chemoresistance. Mutations and deletions of tumor suppressor genes may appear in the 
relapse blast cells that were not present in the initial cell population [93]. For example, a study 
by Hof and colleagues determined that p53 tumor suppressor gene, deleted in over 10% of the 
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relapse population, was correlated to a poor prognosis [100]. Deletions of the zinc finger 
protein IKZF1 were commonly identified in patients with relapsed Ph+ B-ALL [101, 102]. In 
these studies, IKZF1 deletions were correlated with a negative prognosis compared to patients 
diagnosed with Ph+ B-ALL in which IKZF1 was still present [93, 101, 102]. Resistance to 
prednisone and mercaptopurine treatment was also linked to deletions of MSH6, a gene in the 
mismatch repair pathway, leading to overall poor patient outcomes [103, 104]. Additionally, 
prednisone resistance has been linked to mutations of glucocorticoid receptors in the relapse 
population [95, 104, 105]. In general, a patient’s response to prednisone administration is a 
determining factor in development of treatment resistance or disease relapse [68]. Hence, 
patients having a decreased response to prednisone treatment also have higher rates of 
resistance and relapse after initial induction therapy [68]. In other cases, epigenetic 
mechanisms play critical roles in development of resistance to treatment [106]. 
 At the time of relapse, protocols are implemented for risk stratification [33, 93, 107]. 
Time since complete remission is the most important factor in determining a positive or 
negative prognosis [33, 93, 107]. Patients can be placed into one of three different categories 
depending on the time between complete remission and relapse [33, 107]. Generally speaking, 
patients who relapse less than 36 months after remission are considered the most difficult to 
treat and have the worst prognosis with an overall survival rate of less than 30% [33, 93, 107, 
108]. On the contrary, patients relapsing after three years are easier to treat, as demonstrated 
by an overall survival rate exceeding 50% [33, 93, 107]. Another risk factor taken into 
consideration are the sites of relapse [33]. Most commonly, isolated marrow relapse occurs in 
approximately 60% of the time and is correlated to a negative prognosis [33, 109]. The 
majority of remaining extramedullary relapse cases are located in the CNS and testicles, 
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comprising approximately 25% and 5%, respectively [33, 109]. In some rare situations, a 
combination of bone marrow and extramedullary relapse can occur, faring a negative 
prognosis [33, 109]. Furthermore, because patients diagnosed with T-ALL have a greater 
chance of relapsing early compared to patients with B-ALL, they are more often correlated 
with a poor outcome [93, 109, 110]. Unfortunately, between 7-23% of patients with T-ALL 
relapse will have a 5-year overall survival, indicating the need for new types of therapies [93, 
109, 110].  
 With the development of novel chemotherapy drugs that are capable to reduce the 
incidence of CNS and testicular relapse, isolated extramedullary relapse – or relapse occurring 
in sites other than the bone marrow – is uncommon nowadays [111]. Patients with isolated 
CNS relapse are defined as having leukemic blasts in the cerebral spinal fluid (CSF) without 
any blasts present in the medullary compartment of the bone marrow [111]. Similarly, patients 
with isolated testicular relapse do not have blast cell accumulations in the bone marrow but 
will experience enlargement of one or both testicles due to blast infiltration [111]. According 
to the majority of research on relapse patients, the main reason why these two organs are ideal 
sanctuary sites for leukemic blasts is the inability for chemotherapeutic agents to penetrate the 
blood-brain and blood-testes barriers [111]. Other studies on testicular relapse cases points 
towards a cooler temperature in the testes compared to the rest of the body as another potential 
reason of relapse, which may lead to decreased efficacy of certain chemotherapy drugs at that 
location [112].  
 Some important factors at the time of diagnosis can actually predict which patients are 
predisposed to isolated extramedullary CNS or testicular relapse [111]. For instance, in 
patients with T-ALL, certain chromosomal translocations such as t(4;11) forming the MLL-
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AF4 fusion protein and t(9;22), and presence of blast cells in the CNS at the time of diagnosis 
are all predictors of CNS relapse [113, 114]. In addition, patients diagnosed at an older age 
and who have a delayed response to induction therapy are also more prone to isolated CNS 
relapse [113, 115]. Moreover, patients diagnosed with T-ALL during the early puberty years 
are more prone to developing an isolated testicular relapse [116].  
 Once risk stratifications have been established, there are multiple ways to go about 
treating patients experiencing a relapse. Depending on their risk stratification, most patients 
undergo strict treatment regimens that will decrease blast counts in their sites of relapse. For 
example, treatment schedules for high-risk patients will include multi-drug chemotherapy 
combinations prior to undergoing hematopoietic stem cell transplantation (HSCT) once second 
remission is achieved [73, 117-120]. On the other hand, low and intermediate risk patients will 
undergo intensive rounds of chemotherapy without HSCT [73, 117, 118]. Importantly, the 
cytotoxic drugs used in relapse reinduction were ones not previously used in the initial 
induction phase [93]. Unfortunately, finding the best drug combinations for relapse patients is 
extremely difficult and not much progress has been made over the past 20 years in increasing 
overall survival [93]. In cases of isolated CNS and testicular relapse, intensive chemotherapy 
regimens using high-doses of methotrexate, cytarabine, steroids and asparaginase are 
undertaken [121, 122]. In some testicular relapse cases, removal of the affected enlarged 
testicle is sometimes performed [118, 123]. Usually, unilateral or bilateral testicular irradiation 
is also completed to prevent any subsequent disease [118, 123].  
 Unfortunately, even after breakthrough discoveries in pediatric ALL treatment, many 
patients experience multiple relapses. In addition, their chances of overall survival decrease 
for every ensuing relapse from approximately 44% to 27% in second and third relapses, 
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respectively [93, 124]. Another point that raises concern is the inability to treat some patients 
adequately after first relapse since they experience high toxicity and many devastating side-
effects due to treatment [93, 125, 126]. Hence, novel treatment methods need to be developed 
and implemented in order to achieve better overall survival rates for pediatric ALL patients, 
preferably using less cytotoxic compounds.  
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2.2 Pediatric AML, Current Treatments, and Relapse 
 
2.2.1 Biology of pediatric AML 
 
 Acute myeloid leukemia, also known as acute non-lymphoblastic leukemia, is a 
heterogenous malignant disease affecting myeloid, erythroid, and megakaryocyte cell 
precursors [11, 127, 128]. Overall, long-term survival in pediatric AML cases has dramatically 
improved over the years, reaching roughly 50-65% in developed countries worldwide [11, 27]. 
 AML can be subdivided into seven different classes in adults and children according to 
the French, American, and British (FAB) and World Health Organization (WHO) 
classification systems depending on the blood cell progenitor affected and its level of 
differentiation [129]. For a detailed list of AML subtypes according to FAB classifications, 
see table 1.  
Table 1: The French, American, and British (FAB) classifications of AML 
FAB Classification AML Subtype 
M0 Undifferentiated AML 
M1 Acute myeloblastic leukemia without maturation 
M2 Acute myeloblastic leukemia with maturation 
M3 Acute promyelocytic leukemia 
M4 Acute myelomonocytic leukemia 
M5 Acute monoblastic leukemia 
M6 Erythroblastic leukemia 
M7 Acute megakaryoblastic leukemia 
 
 AML is a multifactorial disease involving cooperative mechanisms between several 
cellular pathways in order to trigger disease onset [130, 131]. Development and progression of 
AML requires two important genetic abnormalities classified as being either type 1 or type 2 
mutations [14, 132, 133]. Type 1 mutations affect genes involved in the signal transduction 
pathways which increases cell proliferation and inhibits apoptosis, whereas type 2 mutations 
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include chromosomal rearrangement of transcription factors resulting in formation of fusion 
proteins that impair differentiation processes [14, 134]. Consequently, when both type 1 and 2 
mutations are present at a given time, the resulting groups of cells acquire a high self-renewal 
capacity and an uncontrollable proliferative ability leading to onset of AML [134].  
 Like ALL, there are numerous predispositions associated with AML. For instance, 
peak age incidence for pediatric patients is either in the first four weeks after birth (also 
referred to as congenital leukemia) or during adolescence, with boys being more prone to 
developing the disease [11]. In addition, children with Down syndrome have a higher risk of 
developing AML; however, these patients are very well treated, with overall survival attaining 
85% [135, 136].  
 After diagnosing pediatric AML, patients undergo risk stratification assessments in 
order to determine appropriate treatment methods to attain long-term survival [11, 27]. The 
most important risk consideration is age: adolescent patients have a worse prognosis compared 
to patients below two years of age [11]. In addition, obese patients tend to be negatively 
correlated with long-term survival [11]. Patients with M0 and M7 subtypes are usually 
correlated to prominent treatment responses [11]. Other characteristics like the t(8;21) and 
t(15;17) chromosomal translocations are generally correlated with positive outcomes [11]. 
Another important risk factor taken into consideration prior to beginning treatment is high 
blast concentrations at diagnosis, which is usually indicative of a resistant disease associated 
with very high death rates [137]. Because onset of AML is linked to many mutated genes, one 
way to improve treatment methods is to identify and target these mutations prior to beginning 
chemotherapy. The ability to detect chromosomal aberrations and genetic mutations in AML 
is critical since they are also found to play important roles in relapsed and resistant AML 
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[127]. For example, high levels of AML1-ETO or CBFB-MYH11 fusion proteins are known 
to be associated with decreases in both patient survival and treatment responses [127, 138]. 
Hence, by specifically targeting these fusion proteins in personalized therapies, patients can 
potentially achieve better outcomes.   
   
2.2.2 Treatment of pediatric AML 
 AML treatment consists of induction and consolidation therapies. First, induction 
therapy specifically aims at decreasing leukemic cell concentrations in order to attain 
remission [11, 139]. Induction therapy in AML involves combining cytosine arabinoside with 
either doxorubicin or daunorubicin [11, 139]. For higher risk AML patients, additional drugs 
are administered, such as etoposide and thioguanine [11, 139]. Similarly to ALL therapy, CNS 
directed therapy is also given to patients in order to prevent leukemic blast homing into the 
CNS [127].  
 Once remission is attained, the second phase of treatment, termed consolidation 
therapy, is initiated. Consolidation therapy involves administration of cytosine arabinoside and 
etoposides at very high doses [11, 139]. In some patients, certain cytogenetic aberrations are 
correlated with negative disease outcomes. Hence, in order to increase their quality of life and 
overall survival, hematopoietic stem cell transplantation is conducted immediately after 
induction therapy [11, 93, 127]. Furthermore, in cases where minimal residual disease (MRD) 
is elevated at the end of the induction phase, patients undergo hematopoietic stem cell 
transplantation (HSCT) in order to prevent any occurrence of relapse [73, 93, 101, 140].  
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2.2.3 Relapse of pediatric AML 
 
 Despite recent treatment advances, approximately 35-45% of pediatric patients 
diagnosed with AML will experience a relapse [9, 141-143]. The two most common relapse 
sites are the bone marrow and CNS, the former being much more prevalent than the latter 
[127]. Patients who experience a relapse immediately undergo reinduction therapy. In AML, 
drugs used in treating relapsed patients include cytarabine, fludarabine, and anthracycline 
[144, 145]. In addition to these drugs, patients also receive CNS targeted therapy to limit 
leukemic cell infiltration into sanctuary sites [127]. Ideally, once second remission is attained, 
patients receive HSCT [127].  
 
  
 3.0 Epigenetics   
 
 Epigenetics is the study of any cellular event that changes gene activity or expression 
without changing the actual DNA sequence [146]. These changes in gene expression can then 
be passed down to daughter cells during meiosis and mitosis [146-149]. Many types of 
epigenetic modifications exist in order to conduct cellular epigenome reprogramming that are 
regulated by a variety of different enzymes [146, 147, 149, 150]. Other than methylation and 
acetylation – the two most studied types of modifications – epigenetic regulation can also be 
directed by phosphorylation, ubiquitination, and sumoylation [146, 147, 149, 150].    
 The field of epigenetics can be separated into three main classes: DNA methylation, 
chromatin modifications, and microRNAs [146, 151]. Overall, epigenetic changes are 
necessary for normal cell development, differentiation, and survival; hence, any deregulations 
in epigenetic pathways may have drastic consequences on the cell’s phenotype [146, 147, 149, 
150]. Unlike somatic mutations, changes to a cell’s epigenome are actually reversible and 
therefore constitute interesting therapeutic targets [152, 153].  
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Figure 5: The three classes of epigenetic modifications. 
(1) DNA methylation affects cytosine residues (red circles) of CpG sites on primarily on 
promoter regions. (2) Post-translational histone modifications occur at different histone tail 
residues. H3 and H4 subunits are most studied regarding gene expression patterns. (3) RNA-
based mechanisms by short noncoding RNA sequences, such as micro-RNAs also regulate 
gene expression levels. These sequences are transcribed from DNA but do not undergo 
translation [154]. 
  
 Epigenetic proteins can be functionally characterized as being writers, erasers, or 
readers [155, 156]. Epigenetic writers are enzymes that transfer epigenetic marks onto histones 
or DNA residues [155, 156]. Popular epigenetic writers are histone and DNA 
methyltransferases (DNMTs) and histone acetyltransferases (HATs) [156]. On the contrary, 
epigenetic erasers remove epigenetic marks from histones and DNA (i.e. histone and DNA 
demethylases and histone deacetylases) [156]. Finally, epigenetic readers are proteins that 
bind onto these epigenetic marks, thereby transmitting an epigenetic signal by either activating 
or silencing gene transcription through recruitment of other proteins [156]. There exist many 
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types of epigenetic readers that bind to the multitude of epigenetic marks previously 
mentioned. For instance, the bromodomain proteins recognize histone residue acetylation, 
whereas Methyl CpG binding protein 2 (MeCP2) binds onto methylated DNA residues [156].  
 
 
Figure 6: Examples of epigenetic readers, writers, and erasers. 
Depending on their function, epigenetic enzymes can be classified as being writers, erasers, or 
readers [157].   
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3.1 DNA Methylation 
 
 DNA methylation refers to covalent addition of a methyl group by a DNMT enzyme to 
cytosine residues located primarily on CpG dinucleotides. The methyl group donor for this 
reaction is S-adenosyl-L-methionine (SAM) [158]. Areas in the genome are enriched in CpG 
sites, which are refered to as CpG islands. These genomic DNA sequences are defined as 
stretches of approximately 200 base pairs comprising of more than 50% cytosine and guanine 
repeats [159]. CpG islands are scattered throughout the human genome, but are more 
concentrated in repetitive sequences, imprinted genes, and over half of gene promoters [160-
162]. In normal cells, DNA methylation is required for maintaining a given gene expression 
pattern when genetic material is passed from mother cell to daughter cells [151]. It is also 
necessary in genetic imprinting and X chromosome inactivation [160, 163-165]. In addition, 
CpG island methylation is necessary for cell differentiation and normal cell development 
[162]. It has also been shown to play important roles in expressing tissue-specific genes [162].  
 There are four main types of DNMTs: DNMT1, DNMT2, DNMT3a, and DNMT3b. 
DNMT1 is required for maintaining a cell’s methylation patterns as it divides into two 
daughter cells thereby transmitting epigenetic information from one generation of cells to the 
next [160, 166, 167]. Hence, as a cell divides, DNMT1 uses the parental strand as a template 
to appropriately conserve methylation patterns [160, 165]. On the other hand, DNMT3a and 
DNMT3b are enzymes responsible for addition of new methyl groups to cytosine residues that 
were not previously methylated, also known as “de novo” DNA methylation. Interestingly, 
DNMT2 does not methylate DNA sequences, but targets cytosine residues in transfer RNA 
(tRNA) instead [168].  
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 DNA methylation can lead to gene silencing by a variety of different mechanisms. 
First, DNA methylation acts as a direct transcriptional silencer mainly by recruiting DNA 
methylation readers, also known as methyl-binding domains (MBD) and other chromatin 
repressor complexes onto CpG islands of gene promoters [150, 169-171]. There are five MBD 
proteins identified thus far, with the most studied one being MeCP2 [169]. Once bound onto 
methylated cytosine residues, these MBD proteins are able to recruit additional co-repressors 
that induce changes in chromatin structure, leading to gene silencing [169]. Types of co-
repressors recruited by MBD proteins include histone methyltransferases (HMTs) and histone 
deacetylases (HDACs) [172]. In this manner, DNA methylation alters chromatin dynamics 
that will influence gene expression. In order to activate gene transcription, transcription factors 
bind onto unmethylated CpG islands in promoter regions. Hence, by methylating CpG islands, 
transcription factors are blocked and cannot accomplish their function [169, 170, 173]. 
Another means of gene silencing induced by DNA methylation is recruitment of methyl-
binding proteins (MBPs), which bind onto methylated cytosine residues and prevent the 
binding of transcription factors [169, 170, 173].  
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Figure 7: Differences in DNA methylation levels between normal and cancerous tissues. 
 In normal tissue, lack of DNA methylation on promoter regions of tumor suppressor genes 
allows transcription to be initiated and expression to be turned on. In regions of repetitive 
elements, oncogenes, and transposons, promoter hypermethylation allows gene expression to 
be turned off. In cancer, a hypermethylated promoter for tumor suppressor genes is indicative 
of transcriptionally inactive genes. On the other hand, promoters for imprinted genes, 
repetitive elements, transposons, and oncogenes are hypomethylated, allowing gene 
expression. Figure taken from Sharma and colleagues [150].  
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3.2 Histone Post-Translational Modifications 
 
 The ability for a cell’s nucleus to contain very long strands of DNA would not be 
accomplished without the presence of histone proteins [174, 175]. DNA is tightly wrapped 
around histones to form nucleosomes [147, 174, 175]. The nucleosome is formed by a histone 
octamer [147, 174]. Each octamer is made up of four histone proteins that form the 
nucleosome core: H2A, H2B, H3, and H4 [147]. Nucleosomes are connected to one another 
by linker DNA and are packed together to form chromatin [147, 174].  
 
Figure 8: Nucleoprotein complex of DNA and histone forms chromatin. 
DNA is wrapped around a histone octamer made up of two copies of each histone subunit 
forming a nucleosome. Each nucleosome is separated by spacer DNA [176]. 
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 Each histone contains a C-terminus region, which forms the globular portion of each 
nucleosome, and an N-terminus region, forming a tail that can be covalently modified post-
translationally by a variety of different enzymes. Depending on the post-translational 
modifications, chromatin can be either loosely or tightly organized, referred to as euchromatin 
and heterochromatin, respectively [147, 174, 177]. Whereas euchromatin favors gene 
transcription, heterochromatin is so tightly configured that gene transcription is almost non-
existent [147, 174, 178]. The two most commonly studied histone modifications are 
acetylation and methylation [147, 150]. Other post-translational modifications that play a role 
in gene expression changes include phosphorylation, sumoylation, and ubiquitination [147, 
150].  
 Fascinatingly, two models exist regarding the effects of histone acetylation on 
structural chromatin changes and regulation of gene expression. The first model describes 
acetylation of histone H3 and H4 subunits playing key roles in changing chromatin polarity 
[147]. The abundance of lysine residues on histone tails makes them inherently positive in 
polarity [147]. Hence, when lysine residues are not acetylated, they are tightly compacted with 
the negatively charged DNA strands to form heterochromatin [147]. On the other hand, when 
lysine residues are acetylated, the positive charges are neutralized, supporting the loose 
chromatin structure favoring gene transcription [147]. In the second model, however, 
acetylation of lysine residue 14 on histone 3 (H3K14ac) by P300 induces nucleosome eviction, 
mediated by the histone chaperone Nap1 [179]. Once the nucleosome is removed, 
transcription factor complexes are assembled and gene expression is turned on [179]. Luebben 
and colleagues demonstrated the importance of H3K14ac in mutation studies where they 
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mutated lysine residues on histone H3 and realized that transcription was inexistent, 
demonstrating the necessity of H3K14ac in nucleosome eviction and gene transcription [179].  
 Acetylation and methylation of histone tail residues is regulated by enzymatic 
reactions involving epigenetic writers and erasers [2, 147]. HATs and HDACs are enzymes 
involved in adding and removing acetyl groups on histone residues, respectively [2, 147]. 
Histone methyltransferases (HMTs) and histone demethylases (HDM), on the contrary, are 
involved in adding and removing methyl groups, respectively [2, 147].  
 Compared to DNA methylation, histone modifications are more complex in terms of 
activating or repressing gene transcription [150, 174]. Two factors come into play when 
studying gene expression changes from histone modifications [150, 174]. First, the type of 
modification present on a tail residue will determine whether gene transcription will be active 
or repressed [150, 174]. Second, the position of the modified tail residue will influence 
formation of either euchromatin or heterochromatin [150, 174]. In most cases, histone tail 
acetylation is associated with an increase in gene expression [150, 180]. Histone tail 
methylation, on the other hand, can either be an activating or repressive mark, depending on 
the position of the histone residue [150, 181]. In addition, when referring to methylation, 
histone residues (either lysine or arginine) can either be mono-, di-, or trimethylated; the 
number of methyl groups added to a given residue can also determine whether genes are 
transcriptionally active or repressed [150, 181].  
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Figure 9: Histone tail modifications. 
 a) Schematic representation the four histone subunits (H2A, H2B, H3, and H4) forming an 
octamer. Linker DNA strands connect adjacent nucleosomes. Green circles show possible 
post-translational histone modifications. b) The most studied histone tail modifications on H3 
and H4 subunits. The two most commonly studied histone tail modifications are acetylation 
(Ac) and methylation (Me). With regards to methylation, histone tail residues can be mono-, 
di-, or trimethylated. Loss and gain of acetylation or methylation is depicted as either green or 
red, respectively. Most commonly studied histone residue affected by post-translational 
modifications is lysine (K). Figure taken from Fullgrabe and colleagues [182].  
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3.2.1 Histone Acetyltransferases  
 
 With regards to activation of gene transcription, histone acetylation is by far the most 
studied post-translational modification. HATs will be classified under MYST, GNAT, or CBP 
HAT families [2, 180, 183]. In addition, all HATs share one common feature: they all use 
acetyl-CoA as an acetyl group donor in their enzymatic reactions [184, 185].  
 The MYST family of HAT enzymes has five key members in mammals: HBO1, MOF, 
MORF, MOZ, and TIP60 (table 2) [147, 183-186]. The defining feature of all HATs in this 
family is the presence of a MYST domain and a histone acetylation reader domain termed 
“bromodomain”. This particular domain is a fusion between an acetyl-binding motif and a zinc 
finger. Depending on their binding partners, MYST HATs exhibit different functions, either 
oncogenic or tumor suppressive. For example, members of this family are able to act as 
transcriptional co-activators for important proteins regulating cell proliferation and survival 
pathways such as NF-κB and the oncogene C-MYC [184, 185]. They can also assume 
apoptotic and anti-proliferative functions by activating the apoptosis pathway via p53 
acetylation [185]. They have also been linked to activating genes involved in response to DNA 
damage and repair, such as ataxia telangiectasia mutated (ATM), a protein involved in p53 and 
and γ-H2AX phosphorylation [183]. Once phosphorylated, both proteins activate and recruit 
DNA repair machinerie to the necessary sites [185].    
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Table 2: The MYST HAT family and their target histone subunits. 
HAT Enzyme Target Histone(s) Complex 
MOZ H2A,H2B,H3,H4 - 
TIP60 H4, H3, H2A TIP60 complex 
HBO1 H3,H4 HBO1 complex 
MOF H4*, H3, H2A MSL complex 
MORF H4,H3 - 
*: Preferred target 
 There are three major enzymes that make up the GNAT family of HATs in humans: 
GCN5, PCAF, and HAT1 (table 3) [183, 186, 187]. Members of the GNAT family contain a 
HAT domain and a bromodomain and preferentially acetylate residues on the H3 histone 
subunit [183]. Along with the MYST family of HATs, GNAT also acetylates the tumor 
suppressor p53, thereby activating its apoptotic functions [188].   
Table 3: The GNAT HAT family and their target histone subunits. 
HAT Enzyme Target Histone(s) Complex 
GCN5 H3*, H4 STAGA and TFTC complex 
PCAF H3*, H4 PCAF complex 
HAT1 H4, H2A HAT1 complex 
*: Preferred target 
 Members of the CBP HAT family are slightly different from members of the other two 
classes for two main reasons (table 4). First, the structure of CBP HATs differs significantly 
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when compared to the other two classes [189]. Unlike the other two classes, CBP and P300 
contain cysteine-histidine rich regions (C/H rich-2 and C/H rich-3 regions) [190]. Second, 
dissimilarities in the interacting proteins – and consequently in protein complexes – are also 
observed [189]. Other than acetylating histone residues, these proteins are also involved in 
acetylating p53 tumor suppressor gene, thus mediating apoptosis [183]. It has been recently 
shown that CBP and P300 are involved in acetylating proteins that shuttle between the nucleus 
and the cytoplasm [191].    
Table 4: The CBP and P300 HATs and their target histone subunits. 
HAT Enzyme Target Histone(s) Complex 
CBP H2A, H2B, H3, H4 - 
P300 H2A, H2B, H3, H4 - 
  
 Although all HATs share very similar core domain structures across all three families, 
each enzyme will have specific histone and residue targets on histone tails, primarily lysines 
on either histones H3 or H4 [183, 190, 192]. For example, members of the GNAT family are 
more specific for H3 tail residues, whereas MYST members prefer H4 substrates [183, 190, 
192]. The CBP/P300 family does not have a specific preference on any histone subunit and 
acetylates H2A, H2B, H3, and H4 subunits at equal frequencies [183, 190, 192]. In addition, 
the ability for HATs to form protein complexes with members same family further increases 
both activities and their targets [183, 190, 192]. 
 A very important relationship exists between histone acetylation and epigenetic 
readers, since initiation of gene transcription is often dependent on both of these proteins [106, 
155, 193, 194]. Three main types of histone acetylation readers have currently been 
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discovered, with the most characterized family being the bromodomains [155]. Recently, two 
other types of histone acetylation readers have been discovered: the PHD finger domain of 
DPF3b zinc finger protein and the double pleckstrin homology domain of RTT106 chaperone 
[195, 196]. Overall, epigenetic readers have a strong affinity for consecutive acetylated 
histone residues and are occasionally required for transcription factor activity to be completed 
[155].  
 
3.2.2 Histone Deacetylases 
 
 HDACs are epigenetic erasers that remove acetylation from histone tail residues. They 
can be separated into four main classes, depending on their tertiary peptide sequences, cellular 
localization, and functions. HDACs 1, 2, 3, and 8 are located in the cell nucleus, making up 
class I [2, 174, 197, 198]. Class I HDACs play key roles in deacetylating histone proteins in 
the nucleus [2, 174, 197, 198]. Class II HDACs (4, 5, 6, 7, 9, and 10) are present in the 
cytoplasm and the nucleus, functioning as a deacetylating enzyme on non-histone proteins [2, 
174, 197]. The Sirtuin family of enzymes (sirtuin 1-7) makes up HDAC class III [2, 174, 197]. 
Finally, HDAC11, a cytoplasmic protein, is the only enzyme making up class IV [2, 174]. 
Since it exhibits sequence homology to both classes I and II, HDAC11 is considered a hybrid 
between both HDAC classes [2, 174, 197]. Interestingly, HDACs of different classes are 
known to interact with each other when performing their functions; in some cases, they even 
form protein complexes on histone tails [2, 174, 197]. In order to accomplish protein 
deacetylation, HDACs require cofactors [2, 174, 197, 198]. Classes I, II, and IV require Zn2+, 
while the sirtuin family requires NAD+ [2, 174, 197, 198].   
 4.0 The C-MYC Oncogene in Leukemia 
 
 In cells displaying a normal phenotype, C-MYC is a master transcription regulator that 
plays important roles in a variety of different cellular processes like cell cycle progression, 
protein synthesis, cell adhesion, and apoptosis [199, 200]. Hence, expression levels of the C-
MYC transcription factor are tightly regulated via mRNA and protein mechanisms. Short C-
MYC mRNA half-life and stability triggers its rapid degradation when normal cells do not 
present necessary upstream signals [201]. Additionally, post-translational modifications like 
ubiquitination, acetylation, and phosphorylation of specific residues on the C-MYC protein 
modify its half-life, thereby regulating the amount of proliferative MYC-target genes activated 
at a given time [201-206]. Hence, all these factors aimed at maintaining C-MYC at low levels 
prevent cells from undergoing cellular transformation into a hyperproliferative phenotype 
[201].  
 
 
Figure 10: Structure of the human C-MYC oncogene. 
The C-MYC oncogene is divided into three main regions identified as N-terminal domain 
(NTD), the central region, and the C-terminal domain (CTD). The NTD contains the three 
Myc-box regulatory motifs. The central region contains the nuclear localization sequence 
(NLS). The CTD contains the basic helix-loop-helix domain, as well as the leucine zipper. 
Depicted in the figure is the interaction between C-MYC and Max in the C-terminal domain. 
Figure taken from Chen and colleagues [200].  
 43 
 The human C-MYC protein is a member of the helix-loop-helix leucine zipper 
transcription factor family. It contains a transactivation domain in the N-terminal portion 
[200]. In addition, there are three MYC-box segments (MBI, MBII, MBIII) that contribute to 
the function of the protein [207, 208]. The C-terminal region contains the important helix-
loop-helix region that enables its association and dimerization with the MYC-associated factor 
X (MAX), forming a protein complex that activates transcription of MYC-target genes [201, 
209-211].  
 C-MYC is required in hematopoiesis and lymphopoiesis [212]. Many hematopoietic 
progenitors are in a C-MYC protein equilibrium, which is required to drive normal blood cell 
development [212, 213]. C-MYC plays a critical role in determining whether a hematopoietic 
stem cell will undergo self-renewal or differentiation [212, 213]. In cases of C-MYC 
overexpression, a hematopoietic stem cell (HSC) will differentiate instead of self-renewing 
[212, 213]. On the other hand, when C-MYC expression is low, HSC undergo self-renewal 
[212, 213]. Furthermore, C-MYC expression is necessary for both B- and T- lymphocytes 
differentiation and receptor formation [212, 214-217]. 
 In tumor cells, all the regulatory mechanisms controlling C-MYC mRNA and protein 
stability are dysfunctional [211, 218]. The C-MYC promoter is frequently the target of many 
cell-signaling pathways that are aberrantly overexpressed, such as WNT, RAS/RAF/MAPK, 
JAK/STAT, and NF-κB [201, 211]. Hence, these changes induce an increase in both C-MYC 
protein levels and function, leading to increases in C-MYC target genes and forcing cells to 
proliferate at very high rates [201]. In other cases, C-MYC is constitutively expressed because 
of activation mutations or chromosomal translocations [201, 218-221]. For these reasons, C-
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MYC expression and function are greater than any other oncogene in human cancers, 
especially in sarcoma, leukemia, lymphoma, and myeloma [201, 222-225].    
 Before upregulating expression of its target genes, the MYC-MAX complex recruits 
additional proteins to transcription start sites. Some of these proteins regulate chromatin 
dynamics by acetylating histone tail residues (HATs GCN5 and CBP) thereby exposing 
transcription start sites, while others influence activity and recruitment of RNA polymerases 
and other transcriptional regulators [201, 211, 226]. Overall, the MYC-MAX complex is 
involved in cellular transformation by increasing expression of genes involved in cell 
proliferation, cancer metabolism, and protein biosynthesis, thus inhibiting expression of 
important tumor suppressor genes [201, 211, 227].  
 Although C-MYC is involved in normal blood cell development, it is oftentimes 
implicated in initiation, progression, and resistance to treatment in B- and T- ALL. In vitro 
studies conducted in the 1980s linked high C-MYC expression to development of different 
types of blood malignancies, especially leukemia [228-230]. In these studies, leukemia 
initiation was correlated with the ability to block cell differentiation and initiate abnormal 
proliferation pathways [212, 228-230]. Three chromosomal translocations (t(8;14), t(8;22), 
and t(2;8)) are involved in activation of C-MYC leading to leukemia in approximately 5% of 
adult and pediatric patients [231]. In other cases, C-MYC protein stability is significantly 
increased, thereby stimulating its overall activity [232]. In pediatric B-ALL, C-MYC can 
occasionally be associated with the TEL2 oncogene, which further amplifies development of 
the disease [233]. Cooperation between C-MYC and another oncogene is also observed in T-
ALL patients. Mutations in the NOTCH1 signaling pathway, which are observed in almost 
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50% of T-ALL cases, induce increases in C-MYC mRNA and protein levels, consequently 
leading to target gene activation [225, 234].  
 Unfortunately, the structure of the C-MYC protein and the lack of an active site or 
ligand-binding domain have prevented development of strong inhibitors [200, 207, 235, 236]. 
Recently, many groups have tried developing small molecule inhibitors that will either target 
transcription of the C-MYC gene, the C-MYC/MAX dimerization, or the binding of the C-
MYC/MAX complex onto DNA transcription start sites [200].   
 Another way to indirectly inhibit C-MYC in cancer is to target histone acetylation. C-
MYC is recruited by bromodomains that bind to acetylated histone residues [237, 238]. Hence, 
several researchers have developed a rationale to target these bromodomain proteins in order 
to decrease C-MYC activation by preventing its binding and transcription initiation [237, 238]. 
There are three members of the bromodomain and extra-terminal (BET) family of proteins that 
associate with C-MYC, termed BRD2, BRD3, and BRD4, with the latter being the most 
pertinent in terms of C-MYC association and activation [207, 239].  
 Hence, the link between BET and C-MYC proteins prompted the development of JQ1, 
a selective BET bromodomain inhibitor (BETi), which blocks C-MYC recruitment onto 
acetylated histone tail residues and ultimately blocks transcription of C-MYC target genes 
[240]. Many in vitro and in vivo studies showing promising effects of JQ1-targeted C-MYC 
inhibition on different types of cancers have recently been published [207, 240-244]. 
 JQ1 treatments have shown promising results on B- and T-ALL leukemic cell lines and 
patient samples – including pediatric patients – as well as animal mouse models [239, 243, 
245, 246]. In pediatric precursor B-ALL, Da Costa and colleagues demonstrate that not only 
does JQ1 inhibit C-MYC transcription, but it also decreases its stability [243]. In high-risk 
 46 
pediatric B-ALL models, Ott and colleagues discovered that JQ1 inhibits both C-MYC and IL-
7, two proteins that play crucial roles in development and progression of both B- and T-ALL 
leukemia [239]. In AML, Herrmann and colleagues discovered that JQ1 actually targets 
leukemia stem cells and leukemia progenitor cells, two key players in development of 
leukemia and resistance to cytotoxic therapies [246]. 
 Despite all these promising results, cells develop resistance to JQ1. In fact, some 
leukemia cells do not respond to JQ1 treatment, particularly cells that are associated with 
resistant and relapsed diseases [106, 242, 247]. Despite their promising results, Ott and 
colleagues mention that mice treated with JQ1 eventually die of leukemia, which was, upon 
further analysis, most likely associated with upregulation of C-MYC protein levels [239]. In 
another study, Rathert and colleagues determined that upon JQ1 treatment, AML cell lines and 
patient samples overexpress Wnt signaling genes that confer resistance to treatment [247]. 
Taken together, these studies clearly show a major problem in JQ1 treatments despite 
promising results initially published. Therefore, novel means to inhibit C-MYC must be 
developed in order to target leukemia cancer cells.  
 
  
 
 
 
 
 
 
 
 
 5.0 Epigenetic Aberrations in Cancer 
 
 Over the course of the past ten years, epigenetic alterations have been linked to 
development and maintenance of many types of cancers [147, 248, 249]. At first, many 
researchers believed that cancer was a disease based solely on genetic mutations. However, in 
1983, the first studies – lead primarily by Andrew Paul Feinberg and Bert Vogelstein – linking 
DNA methylation to cancer were published [146, 250-253]. Many research groups then 
focused on epigenetic mechanisms leading to cancer development and subsequent therapies.  
 Cancer is frequently described as having global hypomethylation, with 
hypermethylation at promoter regions [1, 2, 147]. Levels of general hypomethylation can lead 
to expression of genes not usually present on a normal basis, like certain oncogenes and 
transposable elements that may insert themselves into different parts of the genome [161, 254, 
255]. Once transposable elements are actively transcribed, they are able to increase a cell’s 
oncogenic potential by either leading to certain chromosomal abnormalities or inserting 
themselves directly into oncogene sequences [161, 254, 255]. On the other hand, the genes 
usually affected by hypermethylation patterns are very frequently tumor suppressors [147, 
256]. Hence, because DNA methylation patterns are extremely important in disease 
development, they are used for risk stratification in pediatric neuroblastoma and predict a 
complete response in adult CML [257-259].  
 Two studies by Esteller in 2007 and 2008 established the link between histone 
modifications and DNA methylation, and their subsequent effect on gene expression in cancer 
[260, 261]. These studies revealed that two histone modification marks, H4K16ac and 
H4K20me3, are reduced in areas of DNA hypomethylation in repetitive elements, or areas of 
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the genome that are usually silenced [261]. Furthermore, decreases in H3K9ac and 
H3K4me2/3 as well as increases in H3K9me2/3 and H3K27me3 were observed in 
hypermethylated promoter regions of tumor suppressor genes in cancer cells [260].  
 Overall, changes in a cell’s epigenome are important players in cancer development 
and progression [147, 256]. These changes lead to a complete dysregulation of a cell’s normal 
gene expression patterns that lead to a high proliferative potential and an increase in cell 
survival pathways [147, 256].  
  
5.1 Epigenetic Aberrations in Pediatric Leukemia  
 
 Both in AML and ALL, epigenetic modifications lead to silencing of critical tumor 
suppressor genes or activation of certain oncogenes resulting in development of malignant 
cells [262, 263]. Recent whole genome analyses by Downing et al. have demonstrated the 
importance of epigenetic alterations in the development of pediatric cancers in two 
independent studies, including pediatric leukemia [262, 263]. In both studies, they discovered 
that some epigenetic histone-modifying enzymes, such as CREBBP, EED, EP300, EZH2, 
PHF6, and SETD2 are the ones most frequently mutated in AML and ALL, resulting in 
epigenetic deregulation of histone methylation and acetylation levels [262]. In addition, fusion 
proteins containing epigenetic enzymes are also found in pediatric leukemia, which might 
accentuate degrees of histone acetylation or methylation. For example, translocations 
involving the HMT MLL occur in approximately 5% and 10% of pediatric AML and ALL 
cases, respectively [264]. In both leukemia subtypes, a general upregulation is observed in the 
HOX gene family (HOXA3, HOXA5, HOXA7, HOXA9, and HOXA10) [264]. Translocations 
 49 
involving HATs, CBP with either MOZ or MORF, are also observed in certain cases of the 
M5 AML classifications [1, 265].  
 Abnormal DNA methylation patterns also play an important role in silencing or 
activating genes in pediatric leukemia. For instance, genes involved in regulating cell cycle 
checkpoints, such as p15, p16, and p21, and the FHIT and PTEN tumor suppressor genes are 
silenced in pediatric leukemia cases [266]. Other genes silenced in leukemia include ER, 
SDC4, and MDR, and calcitonin [266, 267]. Examples of oncogenes hypomethylated in 
leukemia cases are LINE-1, DEK, and KRAS [161, 267, 268].  
 
5.1.1 Epigenetic Aberrations in Pediatric ALL 
 
 Aberrant DNA methylation in pediatric ALL is one of the hallmarks underlying 
disease development and progression [10, 95, 262, 263, 267]. Increases in DNA methylation 
in pediatric ALL patients are frequently observed around promoters of tumor suppressor 
genes. For instance, many cell cycle regulators like p21 (CDKN1A), p16 (CDKN2A), and p15 
(CDKN2B) are found to be hypermethylated in pediatric ALL compared to healthy cells [269-
271]. In 2014, Chatterton and colleagues compared the methylation status between B-ALL and 
healthy patient samples and discovered a hypermethylated state in 325 genes, whereas 45 
genes were hypomethylated [272]. Amongst the differentially expressed genes between the 
two populations – which included various kinases, cytokines, and transcription factors – they 
observed upregulation of genes involved in cell signaling, cell-to-cell interactions and 
survival. Another study by Nordlund and colleagues in 2013 identified promoters of important 
transcription factors, such as NANOG, OCT4, SOX2 and RESR, to be hypermethylated in a 
large cohort of patients with pediatric ALL [273].   
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 To further emphasize the importance of DNA methylation in pediatric ALL, Figueroa 
and colleagues performed genome-wide cytosine methylation analyses in pediatric B- and T-
ALL patient samples. They determined a correlation between promoter CpG island 
methylation and genetic subtype of ALL (B- or T-ALL), highlighting the importance to 
distinguish methylation patterns at diagnosis prior to starting treatment in order to treat 
specific subsets of patients [267]. Overall, they discovered that genes involved in development 
of B- and T-cell receptors were silenced by hypermethylated promoters [267]. They also 
illustrated that genes involved in cell signaling (TIE1, MOS, and CAMLG) cell cycle 
regulation (DGKG), cell proliferation (MCTS1), transcription factors (PROP1. TAF3, 
H2AFY2, ELF5, and CNOT1) and HOXA gene clusters (HOXA5 and HOXA6) share a similar 
methylation signature between both ALL subtype [267]. Musialik and colleagues discovered 
that genes involved in B-cell development are silenced in some cases of B-ALL. When 
analyzing patient samples, they determined that promoters for genes involved in early 
hematopoiesis (HOXA4 and HOXA5), were hypermethylated and silenced in approximately 
20% of their patient samples with B-ALL [274]. The gene with the most hypermethylated 
promoter was TAL1, a transcription factor regulating hematopoiesis in early progenitor cells 
[274].  
 Not only does DNA hypermethylation play key roles in development and progression 
of pediatric ALL, but it is also implicated in relapse and drug resistance [94, 275]. Whole-
genome methylation studies found that genes were generally hypermethylated in relapse 
patients compared to newly diagnosed patients [105]. In addition, DNA hypermethylation 
levels in relapsed patients may play a role in activating the WNT pathway. Common WNT 
target genes include cadherins proteins (CDH1 and CDH11) as well as SOX genes (SOX2, 
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SOX8, SOX11, and SOX21) making cells prone to proliferating and surviving after 
chemotherapy treatment [105, 276].  
  In addition to changes in DNA methylation, aberrant histone modifications are also a 
determining factor in development of a malignant phenotype [275, 277]. Gain- or loss-of-
function mutations in histone modifying enzymes are frequently observed in pediatric ALL 
cases [275]. Many HAT enzymes, such as GCN5, MYST, and HBO1, were recently 
discovered to be upregulated in B-ALL cases, causing general increases of histone acetylation 
levels [277]. It is important to note that in order to activate transcription, C-MYC is recruited 
to areas of the genome rich in histone acetylation by bromodomains [207]. Hence, when HATs 
are dysfunctional, so is C-MYC target gene expression. Occasionally, HATs acetylate and 
stabilize non-histone proteins that may have roles in development of leukemia. Upregulation 
of GCN5 has been associated with acetylating and stabilizing the E2A-PBX1 fusion protein, 
thus increasing its stability and downstream gene activation [278].  
 Some HATs, such as TIP60, P300, CBP, and GCN5, have also been linked to 
stabilizing the C-MYC oncogene by acetylating certain lysine residues on the protein [205, 
206, 279]. TIP60 and GCN5 specifically target lysines K323 and K417, whereas CBP/P300 
acetylate lysines K143, K157, K275, K317, K323, and K371 [205, 206, 279]. Two of these 
lysines (K323 and K417) are substrates of both acetylation and ubiquitination. Hence, when 
these residues are acetylated, ubiquitination is inhibited, allowing proteins to avoid 
proteasomal degradation [211, 279]. For this reason, acetylation does not only increase 
stability of C-MYC, but it also inhibits its degradation. Unfortunately, the exact mechanism of 
C-MYC acetylation is not yet characterized. Moreover, studies linked high C-MYC expression 
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to decreased overall patient survival and overall in a variety of different cancers, including 
breast cancer, gastric cancer, and leukemia [280-282].  
 In relapse studies, it was determined that mutations in the CBP HAT domain have been 
correlated to poor patient outcome and resistance to treatment [283]. Mullighan and colleagues 
identified a mutation in CBP HAT domain in approximately 20% of relapse cases correlating 
loss of function mutation and resistance to prednisone treatment [283]. Additionally, they 
identified other mutations in epigenetic regulating enzymes such as EP300, EZH2, and CTCF 
present in the relapse patient samples that were either not present at initial diagnosis or they 
were at a very low concentration [283]. However, it is still unclear if these mutations are 
drivers or passengers in ALL. A study on whole genome transcriptome analysis performed on 
relapsed leukemia patient samples found deregulation of the epigenetic modifier PRMT2 as 
well as chromatin modifying proteins CBX3 and MIER3 [284]. Moreover, Inthal and 
colleagues linked CBP HAT domain mutations to cases of hyperdiploid pediatric ALL [285]. 
 Numerous other studies have linked overexpression of HDAC protein levels to poor 
patient outcomes [286, 287]. Moreno and colleagues discovered an upregulation of HDAC6 
and HDAC9 in B-ALL and HDAC1 and HDAC4 in T-ALL [286]. Elevated levels of HDAC4 
have also been shown to play key roles in development of resistance to prednisone in T-ALL 
patients [287]. Other studies conducted on ALL patient samples associated an increase in 
HDAC3, HDAC7, and HDAC9 activity with a poor patient outcome [286, 288]. 
 Furthermore, leukemia is a disorder characterized by the formation of fusion proteins 
[147, 275]. Numerous fusion proteins involving histone-modifying enzymes exist in pediatric 
ALL, and some are actually fundamental in disease development, progression, and relapse 
[147, 283, 285, 289, 290]. In ETV6-RUNX1 and TCF3-PBX1, two subtypes of B-ALL, a 
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gain-of-function mutation of the HMT protein NSD2 induces a conversion of H3K36me1 to 
the silencing histone mark H3K36me2 on promoters of lymphoid developmental genes, such 
as CD69, CD52, NKD2, and CD200 just to name a few [291].  
 The MLL fusion proteins play important roles in leukemia development [264, 292-
296]. In normal cells, MLL has a dual function, primarily in normal hematopoiesis: it acts as a 
transcription factor and an H3K4 methyltransferase involved in transcriptionally active 
chromatin [292, 294, 295, 297]. In order for MLL to activate transcription of its target genes, 
it recruits CBP and MOF in order to further loosen the chromatin structure and upregulating 
MLL-target gene expression [298]. The H3K79 methyltransferase DOT1L interacts with 
MLL-AF9, MLL-AF10, MLL-AF17, and MLL-ENL to increase MLL-target gene 
reactivation. The most studied MLL target genes are the HOX gene family, consisting of 
HOXA and HOXB clusters, involved in normal hematopoietic differentiation into the different 
blood cell lineages [299, 300].  
 In leukemia, MLL is frequently involved in formation of gain-of-function fusion 
proteins that lead to development and progression of leukemia, primarily by increasing 
expression of HOX genes [292, 297]. MLL fusion proteins affect approximately 10% of 
pediatric ALL and over 60% of infant ALL patients [264]. To date, there are over 50 fusion 
proteins identified with the most frequently observed fusion partners being ENL and AF9, 
proteins functioning as transcriptional activators by recruiting the SWI-SNF chromatin-
remodeling enzyme [114, 294, 298]. Other popular MLL fusion proteins include AF4 
(associated with pro-B pediatric ALL), AF6, AF10, and AFX1 [114, 294, 299]. Moreover, a 
study by Zangrando and colleagues identified a unique subset of genes that are upregulated in 
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MLL-rearranged pediatric ALL; this gene list included MEIS1, a protein known to 
upregulated expression of HOX genes required to transform cells into a cancerous state [264].  
  
5.1.2 Epigenetic Aberrations in Pediatric AML 
 
 Recently, sequencing technologies have enabled scientists to discover novel mutations 
in epigenetic enzymes targeting both DNA methylation and histone modifications that play 
roles in development of the disease [301-303]. For example, DNA methylation enzymes 
frequently found mutated in adult AML are DNMT3a, TET2, IDH1, and IDH2 [304]. Other 
enzymes affecting chromatin modifications are ASXL1 and EZH2, as well as all MLL protein 
translocations [304].  
 As in the majority of cancers, DNA methylation levels in AML patients are abnormally 
high in promoter regions and generally low in other parts of the genome [305]. Since 
numerous chromosomal translocations observed in AML affect histone modifying enzymes, 
post-translational modifications in histone tail residues are more commonly associated to 
disease onset compared to DNA methylation levels [306, 307]. Despite drastic differences in 
AML subtypes, when comparing any type of leukemic blast to a normal myeloblast, there is a 
global hypermethylation in the malignant phenotype [304, 308]. Generally speaking, these 
high methylation levels demonstrate the important roles of altered DNA methylation levels in 
development of AML [304, 308].  
 The most common chromosomal translocations in AML involve the histone 
methyltransferase MLL, forming various MLL-fusion proteins involved in H3K4 methylation, 
thereby activating gene transcription [293, 304, 309]. Frequent targets for MLL targeted 
upregulation in AML patients are the HOX genes [304, 309]. Two other histone modifying 
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enzymes involved in translocations are the HATs MOZ and CBP [310]. In addition, 
chromosomal translocations involving RUNX1/RUNX1T1 and PML/RARA form protein 
complexes that change chromatin dynamics to inhibit gene expression [311-313]. Although 
the mechanism is not yet elucidated, these fusion proteins also recruit DNMT enzymes to their 
complexes, which increase DNA methylation levels and repress gene transcription [314, 315].  
  EZH2, an H3K27 trimethylase part of the polycomb repressive complex, is mutated in 
about 2% of AML patients [304, 316]. The complexity in EZH2 function is still not well 
characterized, but recent research on this subject matter point to a dual role as an oncogene 
and tumor suppressor [317, 318]. In AML, EZH2 gain-of-function mutations are associated 
with increased levels of silencing chromatin marks, as well as recruiting DNA 
methyltransferases to promoters of tumor suppressor genes and genes involved in cellular 
differentiation [319-321]. On the other hand, studies on EZH2 loss-of-function mutations have 
reported a shift to a more stem-like state, potentially giving rise to leukemic stem cells. 
Consequently, formation of these cancer stem cells are involved in resistance to treatment and 
disease relapse [317, 319-321].  
 6.0 Epigenetic Therapies 
 
 Although cure rates have dramatically improved over the last 40 years, there are still 
many aspects of treatment that need to be advanced in order to increase remission and reduce 
both relapse rates and short- and long-term toxicity. As mentioned previously, epigenetic 
marks are chemically reversible modifications and can therefore be targeted by drugs that are 
known to induce epigenetic changes [152, 153]. Hence, epigenetic drugs – or epi-drugs – can 
be used to target DNA methylation patterns or induce chromatin remodeling [147, 152, 153, 
249]. By this approach, epi-drugs induce their effects by targeting epigenetic readers, writers, 
or erasers.  
 Currently, the US Food and Drug Administration has approved five epigenetic drugs 
for cancer treatment: two DNA methyltransferase inhibitors (DNMTi) azacytidine and 
decitabine, as well as two histone deacetylase inhibitors (HDACi) vorinostat and romidepsin 
(see table 4) [322-325]. It is important to mention that all four epigenetic drugs approved thus 
far are only used in adults, and no epi-drugs are approved for pediatric patients.   
 
Table 5: Approved epigenetic drugs.  
Name Class Indication 
Decitabine DNMTi Myelodysplastic Syndrome 
and AML 
Azacitidine DNMTi Myelodysplastic Syndrome 
and AML 
Vorinostat HDACi Cutaneous T-Cell Lymphoma 
Romidepsin HDACi Cutaneous T-Cell Lymphoma 
Belinostat HDACi Peripheral T-Cell lymphoma 
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Adapted from Mack and colleagues [326].  
 
6.1 DNA Methyltransferase Inhibitors as Epigenetic Therapy 
 
 Decitabine (5-aza-deoxycytidine) and azacytidine (5-aza-cytidine) both act as 
nucleoside analogs that are incorporated into dividing cells to form a complex with DNMTs 
leading to their degradation, thereby inhibiting their function [327, 328]. When treating 
patients with DNMTi, low-dose treatment induces an epigenetic effect, while high-dose 
treatments induce a cytotoxic effect due to formation of DNA adducts [324, 329]. Therefore, 
by treating patients with low-dose DNMTi, cytotoxic side effects are limited [324, 329].  
 As mentioned previously, promoter regions of tumor suppressor genes in cancer cells 
are found to be hypermethylated, leading to epigenetically silenced gene expression. Other 
than silencing many tumor suppressor genes, DNA methylation changes also affect key 
cellular pathways [330]. Some genes frequently silenced by abnormal DNA methylation 
patterns in cancer include p16 and DAPK involved in regulating the cell cycle and apoptosis, 
respectively. In addition, genes involved in suppression of the WNT signaling pathway and 
DNA repair are two additional targets of DNA hypermethylation leading to gene silencing 
[330]. 
 DNMTi were first introduced in the 1980s as a potentially novel drug for treating 
hematological diseases, including pediatric leukemia [331-334]. The most common side effect 
of DNMTi treatment is myelosuppression [329]. Despite leading to increases in survival and 
overall positive effects, decitabine has some negative points, such as non-specific 
demethylation of target regions, very low stability in solution and short half-life [147, 335]. 
Unfortunately, remission duration for patients treated with DNMTi is generally short, and 
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development of resistance to treatment is oftentimes observed [335]. In order to improve 
DNMT inhibition, researchers began working on several other DNMTi analogs that are more 
stable, more specific, and less toxic than the two original FDA approved drugs [336, 337]. 
These novel drugs, which include DHAC (dihydro-5-azacytidine), FCDR (5-fluoro-2`-
deoxycytidine), zebularine, and SGI-110, are currently in clinical trials [336, 337]. Therefore, 
the need to combine DNMTi treatment to other types of epigenetic or cytotoxic treatments 
may be the key in treating certain sub-groups of patients.  
 
6.2 Histone Modifying Drugs As Epigenetic Therapy 
 
 In normal cells, a balance exists between histone modifying enzymes that add and 
remove epigenetic marks, enabling cells to proliferate at a normal pace, differentiate, and 
eventually activate the apoptosis pathway [336, 338]. Abnormal expression or activity of one 
or more of these histone-modifying enzymes may induce malignant cellular transformation 
that leads to cancer development, mainly by silencing tumor suppressor genes or activating 
oncogenes [336, 338]. The diversity of histone-modifying enzymes enables researchers and 
clinicians to target specific histone modifications, enabling the use of histone-modifying drugs 
as epigenetic therapy [336, 338].  
 
6.2.1 Histone Deacetylase Inhibitors (HDACi)   
 
 HDACi are divided into four different classes according to their chemical structure 
[147, 338]. The four classes of HDACi are short-chain fatty acids, hydroxamic acids, cyclic 
peptides, and benzamides [336]. The vast majority of HDACi, whether they are already 
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approved by the FDA or presently in clinical trials, target HDAC classes I and II [338, 339]. 
Their general mechanism of action is to block the catalytic domain of HDAC enzymes [338]. 
This effect will inhibit HDAC recognizing and binding onto its targets [147, 338]. Overall, 
HDACi induce gene reactivation, cell differentiation and apoptosis in vitro and in vivo [147, 
338, 340]. They also inhibit colony formation and cell cycle progression [338, 340]. Currently, 
there are only three HDACi approved by the FDA for the treatment of cutaneous T-cell 
lymphoma: vorinostat, romidepsin, and belinostat [147, 338, 341, 342]. HDACi increase 
expression of differentiation and tumor suppressor genes in many cancers [336, 343]. It is also 
found to inhibit cell cycle progression by specifically activating p21 and the p53 pathway 
[277]. Vorinostat and other HDACi also exert their effects through induction of oxidative 
stress, and increase in gene expression of cell cycle regulators and cell-surface death receptors 
[198, 277].  
 FDA-approved and newly developed HDACi are currently in numerous clinical trials 
for treatments of many types of cancers including melanoma, meningioma, leukemia, and 
prostate cancer (NCT01265953, NCT02032810, NCT01798901, NCT02282917). These drugs 
are potent anticancer agents in preclinical models, but when administered to patients they have 
limited effect. Hence, recent evidence has emerged questioning the mechanism and efficacy of 
HDACi. Because these compounds increase histone acetylation, they can actually potentiate 
effects of C-MYC recruitment by bromodomains. One study in particular focused on deleting 
HDACs in lymphoma and leukemia that overexpress the MYC oncogene in vivo determined 
that enhancements of oncogenicity were observed in these animals [344, 345].  
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6.2.2 Histone Acetyltransferase Inhibitors (HATi) 
 
 Due to the fact that HATi have been studied less thoroughly compared to HDACi, they 
are much less characterized [336]. Development and testing of certain HATi in vitro on ALL 
cell lines have demonstrated efficacy, but only curcumin, a naturally occurring molecule that 
targets P300/CBP has been integrated into clinical trial testing on pancreatic, colon, and breast 
cancers (NCT02724202, NCT00094445, NCT00192842) and has shown promising results on 
prostate cancer in vitro [277].  
 Structural differences between HAT families have permitted the development of 
molecules that target specific HATs. For instance, α-methylene-γ-butyrolactone 3 (MB-3) 
specifically targets GCN5. MB-3 can potentially be used as a supplement to chemotherapy 
drugs in ALL patients harboring the E2A-PBX1 translocation since GCN5 stabilizes it by 
acetylation [278]. Another molecule currently studied is garcinol, the naturally occurring P300 
and PCAF inhibitor. It acts as a HATi by binding onto two sites located on HATs, the acetyl-
CoA and the histone binding domains, thereby suppressing cell growth [346, 347].  
 Apart from curcumin, CBP/P300 inhibitors include ICG-001, chetomin, and C646. 
ICG-001 inhibits interactions between CBP and β-catenin specifically but has no effect on 
P300 and β-catenin interactions. When tested against pre-B ALL, ICG-001 induced 
differentiation and eliminates all resistant cancerous cells when combined with conventional 
chemotherapy regimens [348, 349]. Moreover, chetomin is a molecule that blocks the 
interaction between CBP and P300 with HIF-1, which induces cell differentiation in a glioma 
cell model [350]. Finally, compound C646 specifically targets ETO driven AML by inducing 
cell cycle arrest and apoptosis [351, 352]. It has also been demonstrated that C646 sensitizes 
melanoma cells to chemotherapy drugs when treated in combination [351]. Other molecules 
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targeting TIP60 are also currently being studied. For instance, anacardic acid sensitizes HeLa 
cells to radiotherapy, whereas NU9056 and TH1834 decrease cell viability in in vitro models 
of prostate and breast cancer cells, respectively [353-355].  
 
6.3 Combinational Epigenetic Therapies 
 
 In general, treating cancer is impossible with single-agent therapy because of tumor 
heterogeneity and rapid development of resistant clones in both leukemia and solid cancers 
[356]. The same is true concerning epigenetic therapies; as a single agent, epigenetic drugs do 
not show strong treatment responses when administered to patients. However, in combination, 
the potential of epigenetic therapy can be efficiently applied. Malignant cancer cells become 
addicted to certain levels of DNA methylation and specific histone tail modifications in order 
to survive [357, 358]. Hence, by targeting more than one epigenetic mark, malignant cells lose 
the ability to express certain key proteins required for their survival. Interestingly, several 
groups have shown promising results in studies that combine epigenetic drugs to either 
immunotherapies or conventional chemotherapy regimens.  
 Another fantastic new method in treating many cancers nowadays revolves around 
immunotherapy. Thus far, patients responding to treatment show elevated overall survival 
rates and extremely promising results [359]. Unfortunately, most patients do not respond to 
immunotherapy treatments and additional measures to ensure increased response need to be 
implemented [111]. The main reason why immunotherapy is ineffective in these patients is 
because cancer cells find ways to evade the host immune system [360-363]. They do so by 
either silencing cell surface receptors critical for tumor cell recognition and destruction or 
overexpressing molecules that generally suppress the immune system [360-363].  
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 The ability for epigenetic drugs to induce reversible changes in gene expression has 
made them interesting candidates for combinational approaches with immunotherapy. Many 
preclinical studies have shown extremely promising results in combining epigenetic drugs and 
immunotherapy. For example, pre-treating cells with epigenetic drugs increases expression of 
antigen-presenting molecules on the surface of tumor cells [364-368]. They have also been 
shown to increase presentation of tumor specific antigen and activating ligands for NK cell-
mediated cytotoxicity [364, 369-371]. All these factors lead to detection and destruction of 
tumor cells by the patient’s immune system. Many ongoing or completed clinical trials 
studying the effects of epigenetic therapy in combination with immunotherapy demonstrate 
the interest in utilizing both methods of treatments for a variety of cancers.   
 
 
Table 6: Selected clinical trials testing epigenetic drugs in combination with 
immunotherapy treatment.  
Clinical Trial Identifier Cancer Epigenetic Drugs and 
immunotherapy 
NCT02546986 Advanced or metastatic NSCLC Azacytidine + Pembroluzumab 
NCT01928576 NSCLC Azacytidine or Azacytidine + 
Entinostat and Nivolumab 
NCT01038778 Metastatic kidney cancer Entinostat + Aldesleukin 
NCT01241162 Neuroblastoma and sarcoma Decitabine + Dendritic cell 
vaccine 
NCT01673217 Recurrent ovarian 
epithelial/peritoneal/fallopian tube 
cancers 
Decitabine+ NY-ESO-1 peptide 
vaccine 
NCT01834248 Myelodysplastic syndrome and AML Decitabine + DEC-205/NY-
ESO-1 fusion protein vaccine 
  
As mentioned previously, epigenetic dysregulation in cancer cells is one important 
reason cells develop resistance to conventional induction chemotherapy treatment. One means 
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to counter resistance in cancers is inducing epigenetic resetting or preconditioning prior to or 
during chemotherapy treatment [372, 373]. However, before combining epigenetic with 
chemotherapy drugs, the exact mechanism of resistance needs to be characterized in order to 
avoid antagonistic actions between them [372, 373]. For example, in some pediatric 
glioblastoma cases, the O-6-methylguanine-DNA methyltransferase (MGMT), DNA repair 
enzyme, is silenced by hypermethylation; treating these patients with DNMTi will activate this 
gene and trigger resistance of these cells to cytotoxic therapy [374]. So far, synergy between 
DNMTi and chemotherapy drugs like paclitaxel and cisplatin have been established in lung 
and prostate cancer cell lines [375-377].  
 Along with DNMTi, HDACi are also promising combination drugs in many cancers. 
Because HDACi facilitate drug-induced apoptosis, combination treatments with chemotherapy 
drugs are promising to counter resistance and reset chromatin to a non-resistance state [198]. 
In general, HDACi are known to synergize extremely well with multiple cytotoxic drugs by 
facilitating apoptosis-mediated cell death, primarily by upregulating apoptosis and 
downregulating cell survival pathways [338, 378]. For example, after pre-treating cancer cells 
with either trichostatin A or vorinostat – two HDACi – Kim and colleagues showed the effects 
of sensitizing cancer cells to chemotherapy; this type of treatment can also be applied to 
resistant cancer cells in vitro or in vivo [379]. Qian and colleagues determined a synergistic 
relationship between HDACi and three cytotoxic compounds, carboplatin, docetaxel, and 
paclitaxel, in ovarian cancer studies in vitro and in vivo [380]. Other known synergistic 
cytotoxic partners for HDACi are gemcitabine, cisplatin, etoposide, and doxorubicin [379, 
381-383]. All in all, preclinical and clinical studies have demonstrated promising results in 
DNMTi and HDACi.  
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 Instead, other groups have opted to combine epigenetic drugs targeting distinct 
epigenetic regulators. The idea behind combining epi-drugs targeting different regulators of a 
cell’s epigenome has been shown to improve efficiency compared to monotherapy [153, 384]. 
In a phase 1 and 2 clinical trial, Garcia-Manero and colleagues tested the combination between 
the DNMTi decitabine and the HDACi valproic acid in patients diagnosed with acute and 
chronic leukemia [385]. In their study, they determined a synergistic relationship between the 
two epigenetic drugs and promising results in terms of gene re-expression of several cell cycle 
regulators and overall patient survival [385]. In some cases, treating with a DNMTi as 
monotherapy is not sufficient. A study by Si and colleagues demonstrated that despite treating 
with DNMTi, some genes were not re-expressed because of silencing chromatin marks [386]. 
This phenomenon was overcome by combining DNMTi to epi-drugs targeting histone 
modifications, thus demonstrating the importance in using a combinatorial epigenetic therapy 
approach to target a bigger subset of cancer cells harboring both aberrant histone 
modifications and DNA methylation levels [386].  
 
Table 7: Selected clinical trials testing epigenetic drugs in combination with cytotoxic or 
other epigenetic drugs. 
Clinical Trial Identifier Cancer Epigenetic Drugs 
NCT00867672 AML Decitabine + Valproic Acid 
NCT02190695 AML-MDS-CMML Decitabine + Carboplatin + 
Arsenic Trioxide 
NCT02159820 Ovarian Cancer Decitabine + Paclitaxel 
NCT01928576 NSCLC Azacytidine + Entinostat 
  
 Finally, combinations of epigenetic drugs with non-cytotoxic molecules have also been 
shown to have promising results. These drug combinations aim to increase response to 
treatment – and potentially synergizing with the epigenetic drug – while limiting toxic side 
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effects altogether. The isoflavone genistein, a compound found in soybeans, is a prime 
example of utilizing these non-toxic molecules shown to have interesting cancer preventative 
properties in treating the disease [387, 388]. Prior to being used as a potential anticancer drug, 
several studies demonstrated genistein’s ability to synergize with chemotherapy medication 
and its ability to increase expression of p15 and p16 tumor suppressors in cancer cell lines 
[389-392]. These findings prompted Raynal and colleagues to test genistein in combination 
with decitabine in their preclinical models for leukemia, in which they found an interesting 
synergistic combination [393]. Clinical trials using the decitabine-genistein combination are 
highlighted in table 8. 
 
Table 8: Clinical trials testing the combination of decitabine and genistein. 
Clinical Trial Identifier Cancer Drugs 
NCT01628471 NSCLC and advanced solid 
tumors 
Decitabine + Genistein 
NCT02499861 Pediatric relapsed or 
refractory cancers 
Decitabine + Genistein 
 
 
 7.0 Background on Project  
 
 Development of new drugs is a very costly and extremely long process. In order for a 
drug to become commercially available, numerous steps must be completed [394]. The first 
step in drug development is identifying a potential target protein or pathway that is 
dysregulated in cancer cells [394]. Researchers then develop drugs to target these proteins or 
pathways in their preclinical studies and animal models [394]. If results are promising, the 
drugs enter clinical trials [394]. Once validated in humans for toxicology and indication, 
drugs are approved by the US Food and Drug Administration (FDA) [394]. Overall, 
development of a new drug costs over one billion dollars and may take up to 15 years before 
finally being FDA-approved [395-397].  
 In order to avoid the lengthy and costly process, drug repositioning – also known as 
drug repurposing – can be conducted to develop new anticancer therapies [395, 396]. This 
process consists of using drugs that are already approved by the FDA for one indication in 
order to treat other disease types, such as cancer [395, 396]. Because drug repositioning uses 
FDA approved drugs that have a long history of preclinical and toxicological studies, they can 
quickly be developed or incorporated into treating cancer without passing through rigorous 
testing [395, 396]. The primary benefits from drug repositioning include much lower cost and 
reduced side-effects compared to cytotoxic therapies currently used [395].  
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7.1 Screening FDA approved drugs for epigenetic and anticancerous properties  
 In 2010, Si and colleagues developed a model to evaluate reactivation of gene 
expression in colon cancer cells after decitabine treatment [386]. In their model, they attached 
a green fluorescent protein (GFP) to a hypermethylated cytomegalovirus (CMV) promoter. 
Hence, if GFP expression is increased, it implies that the drug treatment induces epigenetic 
changes in either a cell’s chromatin structure or DNA methylation levels. Raynal and 
colleagues used the same model in 2012 when they demonstrated two important findings 
[398]. First, they characterized DNA methylation levels as the long-term epigenetic signal in 
determining whether gene expression is turned on or off [398]. Second, they demonstrated the 
importance of chromatin modifications in transient gene expression changes, implying that 
chromatin can potentially be an important target in epigenetic therapies against different 
cancers [398].   
 The same hypermethylated CMV-GFP model was used in 2016, when Raynal and 
colleagues screened over 1,100 FDA-approved drugs to assess for epigenetic and anticancer 
properties using two dose schedules [399]. They separated the eleven most efficient drugs that 
re-expressed GFP into three different classes, from highest to lowest, respectively [399]. The 
first class contained drugs that induced the highest GFP expression; the three FDA-approved 
epigenetic drugs decitabine, azacitidine, and vorinostat were placed in this category [399]. 
Next, the second group of drugs inducing most gene re-expression contained five cardiac 
glycosides  (ouabain, lanatoside C, digoxin, digitoxin, and proscillaridin A) [399]. 
Interestingly, all the cardiac glycosides used in their study stimulated GFP re-expression 
[399]. Finally, the third class contained an antibiotic (oxyquinoline), an anti-cancer drug 
(arsenic trioxide) and a drug used in treating chronic alcohol abuse (disulfiram) [399]. 
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Interestingly, they also demonstrated changes in intracellular calcium levels as a potential 
anticancer mechanism of the drugs displaying newly identified epigenetic properties; these 
same changes in calcium levels were not observed in FDA-approved epigenetic drugs [399]. 
Hence, they suggested that calcium signaling is a key regulator in activating tumor suppressor 
gene expression in cancer cells [399].  
 
7.2 Cardiac Glycosides 
 
 Cardiac glycosides are naturally occurring compounds that can be subdivided into two 
major categories: the cardenolides and bufadienolides [400, 401]. All cardiac glycosides share 
a similar molecular structure consisting of a steroid ring; the steroid ring defines the active 
portion of the molecule [402]. The only structural difference between cardenolides and 
bufadienolides is the lactone moiety which is made up of a four-membered or five-membered 
ring in cardenolides and bufedienolides, respectively [403]. Both classes act as sodium-
potassium (Na+/K+) channel blockers, leading to increases in intracellular sodium levels. 
Increases in intracellular sodium levels induce a diminished activity of the sodium-calcium 
(Na+/Ca2+) pump, thereby leading to increases in calcium levels and cardiac contractility in 
patients suffering from arrhythmias and congestive heart failure [400, 401, 403].  
 Interestingly, cardiac glycoside intake has been correlated to anti-cancerous 
properties. It has previously been shown that patients taking cardiac glycosides during or 
prior to chemotherapy treatment not only have less invasive cancers, but also present a 
decreased mortality risk after induction phase therapy is completed [404-407]. Other 
epidemiological studies have demonstrated a decreased risk in developing leukemia and 
urinary tract cancers in patients who are treated with cardiac glycosides [408, 409]. In other 
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studies, cardiac glycosides were found to block lung cancer cells in the G2/M phase, thereby 
sensitizing them to radiotherapy in vitro [410, 411]. In addition, a study by Felth and 
colleagues demonstrated synergistic and additive effects of different cardiac glycosides with 
cytotoxic chemotherapeutic drugs on colon cancer cell lines, further demonstrating diverse 
anticancer properties [412].  
 Recent studies suggest that cardiac glycosides also activate downstream signaling 
pathways leading to cell proliferation, growth, motility, differentiation, and apoptosis [413-
417]. There are two main means of triggering signaling pathways induced by cardiac 
glycoside treatment. First, cardiac glycosides induce oscillations in intracellular calcium 
levels by activating the phospholipase C and IP3 pathway [418-420]. Depending on the 
calcium concentrations and the duration of the calcium oscillations, cells will either 
differentiate, proliferate, or apoptose [421]. Second, calcium changes are able to trigger the 
RAS-RAF-MAPK cascade. Once activated, RAS induces the release of reactive oxygen 
species (ROS) from mitochondria [403, 422]. These ROS will activate NF-κB, a protein that 
will induce transcription of genes involved in cell differentiation [403, 422].   
 On the other hand, mechanisms inducing anticancer effects by cardiac glycosides have 
not yet fully been characterized, but there are a few potential speculated mechanisms that 
explain the anticancer properties of cardiac glycosides. For example, Kometiani and 
colleagues believe that cardiac glycosides increase expression of the cell cycle regulator p21 
via the MAPK pathway [423]. Some groups have also uncovered an inhibitory role against 
topoisomerase enzymes, while others have identified upregulation of important pro-apoptotic 
genes in T-cell lymphoma, prostate and lung cancers [424-428]. Another means by which 
cardiac glycosides are able to induce anticancer effects is by inhibiting glycolysis. Because 
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glycolysis is upregulated in cancer cells, inhibition of this energy-producing pathway can 
specifically target these cells for destruction [429, 430].  
 All in all, many potential mechanisms underlie the antitumor effects of cardiac 
glycosides; perhaps some mechanisms are activated in specific cell types compared to others 
but these findings have yet to be fully understood.  
7.3 Proscillaridin A 
 
 Proscillaridin A is a member of the bufadienolide cardiac glycoside family extracted 
from the Scilla plant [431]. Interestingly, this cardiac glycoside in particular has been shown 
to have anticancerous activities in many cell lines during drug-repositioning studies [400, 
432, 433]. For example, proscillaridin A induces apoptosis and antiproliferative actions in 
various breast cancer cell lines in vitro, primarily by fluctuations in calcium levels [400, 432]. 
Furthermore, Bielawski and colleagues determined that proscillaridin A inhibits 
topoisomerase enzymes in breast cancer cells, which ultimately leads to cell death [434]. 
Denicolaï and colleagues revealed that proscillaridin A inhibits growth of glioblastoma cell 
lines in vitro, in addition to significantly decreasing tumor volume and increasing survival of 
mice transplanted with glioblastoma cancer cells [433].  
 Unfortunately, proscillaridin A, along with other bufedienolides, have a very small 
therapeutic window – with plasma concentrations between 1 and 10nM in humans – and 
doses need to be very low to limit cardio- and neurotoxicity [435-437]. In a study by Daniel 
and colleagues, cardiac glycosides of the bufadienolide family specifically target T-
lymphoblasts while completely avoiding healthy non-malignant cells [438]. Despite the high 
toxicity risk, proscillaridin A has evident anti-tumor effects that can be used to treat cancer 
patients.  
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Figure 11: Molecular structure of proscillaridin A 
[433] 
 8.0 Hypothesis 
 
 We hypothesize that the cardiac glycoside proscillaridin A will induce anti-leukemic 
effects by an epigenetic mechanism and can therefore be repositioned to treat pediatric 
leukemia.  
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1. Introduction 
 
 Acute lymphoblastic leukemia (ALL) is characterized by genetic and epigenetic 
aberrations that induce a loss of differentiation and an increase in proliferation of lymphoid 
progenitor cells [15, 16]. Depending on the lymphoid progenitor affected, ALL can be 
subdivided into two main categories: B- and T-ALL [16, 17]. In children, ALL accounts for 
approximately 25% of all pediatric cancers with incidence peaking between the ages of 2 and 
5 [18, 19]. Although current treatment methods cure over 85% of pediatric patients, those who 
relapse or become resistant to treatment have a very poor outcome with an overall survival of 
approximately 25% [10, 20]. Because of its high prevalence, relapsed or refractory ALL is the 
leading cause of cancer-related mortality among children [439]. Thus, there is an urgent need 
to develop new therapeutic strategies to increase cure rates for relapsed or resistant pediatric 
ALL.  
 Molecular mechanisms underlying B- and T-ALL development include inactivation of 
tumor suppressor genes and activation of oncogenes [21-23]. Genetic lesions, such as 
abnormal chromosomal numbers, translocations, and mutations are often identified in the 
pediatric ALL population [21-23]. Not only are genetic lesions involved in the development of 
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ALL, but epigenetic alterations have been demonstrated to have prominent roles in 
pathogenesis as well. Aberrant DNA methylation of promoter CpG islands, defined as 
stretches of approximately 200 base pairs comprising more than 50% cytosine and guanine 
repeats, is one of the hallmarks underlying disease development and progression [10, 95, 159, 
160, 262, 263, 267, 440]. For instance, hypermethylated CpG islands in promoter regions are 
frequently observed in tumor suppressor genes, whereas promoters for oncogenes are shown 
to be in a hypomethylated state, correlated to gene silencing and activation, respectively. In 
addition to changes in DNA methylation, aberrant histone modifications are also a 
determining factor in the development of a malignant phenotype [275, 277]. Chromosomal 
translocations and gain- or loss-of-function mutations in histone-modifying enzymes involved 
in adding or removing acetyl or methyl groups on histone tail residues are frequently observed 
in pediatric ALL cases [275, 277, 283-285, 289, 290]. These epigenetic modifications are also 
linked to treatment resistance and disease relapse [94, 275]. Interestingly, because DNA 
methylation and post-translational histone modifications are reversible chemical reactions, 
they have become promising targets for treatment. 
 Currently, there are five FDA-approved drugs – two DNA methyltransferase inhibitors 
(DNMTi) and three histone deacetylase inhibitors (HDACi) – targeting epigenetic 
modifications in adult cancer patients. Notably, none of these drugs are approved for pediatric 
patients. Two DNMTi, decitabine and azacitidine, decrease overall DNA methylation by 
blocking enzymes involved in adding methyl groups to CpG islands, subsequently reactivating 
hundreds of silenced tumor suppressor genes. HDACi, such as vorinostat, romidepsin, and 
belinostat are drugs that lead to general increases of histone acetylation levels. Because 
increases in histone acetylation are correlated to increases in gene expression, the properties of 
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HDACi permit overall epigenetic upregulation. Unfortunately, these epigenetic drugs have 
limited effects in cancer patients. Hence, the need to develop or discover additional epigenetic 
drugs is evident, especially in treating pediatric cancers like ALL.  
 Histone acetylation is catalyzed by histone acetyltransferases (HAT) and is associated 
with euchromatin and transcriptionally active regions. Histone acetylation is removed by 
histone deacetylases (HDAC), which create condensed chromatin leading to gene silencing 
[147]. Recently, decreasing histone acetylation has gained popularity because of its 
involvement in stimulating activity of oncogenic enhancers. Recent epigenomic studies on 
pediatric cancers, including leukemia, have demonstrated that histone acetylation attracts 
bromodomains proteins, which transmit acetylation signals and then recruit oncogenic 
transcription factors, such as C-MYC [106, 194, 441, 442]. Therefore, histone acetylation 
represents an attractive target for epigenetic therapy in pediatric ALL. 
  In order to avoid the lengthy and costly process of approval, drug repositioning – also 
known as drug repurposing – can be conducted to develop new anticancer therapies [395, 
396]. This process consists of using drugs that are already approved by the FDA for one 
indication in order to treat other disease types, such as cancer [395, 396].  Epigenetic drug 
screening on more than 1,100 FDA-approved molecules was conducted to discover drugs with 
new epigenetic and anti-cancerous properties in a preclinical colon cancer model [399]. One 
group of drugs in particular, cardiac glycosides, exhibited the most epigenetically driven gene 
reactivation and robust anti-cancerous properties [399]. Surprisingly, all drugs exhibiting 
newly discovered epigenetic properties were shown to upregulate gene expression of tumor 
suppressor genes by activating calcium-calmodulin kinase pathway [399]. The exact 
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mechanisms of action of these compounds and their tumor specificity have yet to be 
determined.  
 These findings encouraged us to perform a secondary screen on a number of these 
drugs to explore potential epigenetic mechanism and identify cancer specificity among a panel 
of cancer cell lines. Amongst the four compounds tested, we determined that the cardiac 
glycoside proscillaridin A demonstrated the greatest anticancer activity towards pediatric 
leukemia cell lines. Proscillaridin A induced epigenetic effects by decreasing expression of 
HATs TIP60, CBP, and P300 in addition to histone acetylation levels specifically on the H3 
subunits. In addition, we noticed a significant decrease in both C-MYC protein levels and 
expression of its gene targets. Therefore, we showed that proscillaridin A induce a rapid 
degradation of HAT and histone acetylation levels resulting in degradation of the C-MYC 
oncogene in ALL cell lines. In the present study, we demonstrate, for the first time, the 
anticancerous effects of proscillaridin A in pediatric cancer cell lines targeting acetylation to 
reprogram ALL cells both at the levels of oncogenic transcription factors and core histone 
proteins. 
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2. Materials and Methods  
 
Cell Culture and Drug Treatments 
REH (non-T; non-B) leukemia cell line was purchased from American Type Culture 
Collection. Thp-1 (AML) leukemia cell line was purchased from American Type Culture 
Collection. Molt-4 (T-ALL) leukemia cell line was purchased from the American Type 
Culture Collection. Nalm-6 (pre-B ALL) leukemia cell line was purchased from the Leibniz 
Institute DSMZ-German Collection of Microorganisms and Cell Cultures. REH, Molt-4, and 
Nalm-6 cell lines were cultured in Gibco RPMI 1640 supplemented with 10% fetal bovine 
serum at 37°C and 5% CO2. Thp-1 cell line was cultured in Gibco RPMI 1640 supplemented 
with 10% fetal bovine serum and 0.05mM of 2-mercaptoethanol. Proscillaridin A was 
dissolved in 100% dimethyl sulfoxide at stock concentration of 100 mM and stored in -20°C. 
ORFLO MOXI Mini Automated Cell Counter was used to analyze growth inhibition after 
treatment. 
 
Cell Cycle Analysis   
To analyze effects of Proscillaridin A on cell cycle by Fluorescence-activated Cell Sorting 
(BD FACS Canto II), cells were treated with for 48 hours at three different concentrations 
(2.5, 5, or 7.5 nM). Cells were then harvested, fixed, and stained with bromodeoxyuridine 
(BrdU) and/or 7-amino-actinomycin (7-AAD) (BD Pharmingen BrdU Flow Kit). Untreated, 
BrdU-only, and 7-AAD-only stained cells were used to set up compensation controls. 
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Analysis of Whole Cell Proteins by Western Blot  
Cell pellets were lysed in cold whole cell lysis buffer (50mM Tris-Cl pH7.4, 5mM EDTA, 
250mM NaCl, 50mM NaF, 0.1% Triton, 0.1mM Na3VO4, and 1mM PMSF). Lysis buffer was 
supplemented with protease inhibitor cocktail (PIC) and phosphatase inhibitor cocktail 
(phospho-stop). Protein extracts were separated by SDS-PAGE and transferred onto a 
polyvinyl difluoride (PVDF) membrane. The following primary antibodies were used to detect 
expression levels of isolated proteins: TIP60 (1:5000, Active Motif cat#61546), CBP (1:2500, 
Bethyl Labs cat#A-300-362A-T), P300 (1:5000, Active Motif cat#61402), HDAC1 (1:5000, 
Cell Signaling cat#5356), HDAC2 (1:5000, Cell Signaling cat#5113), HDAC4 (1:5000, Cell 
Signaling cat#7628), C-MYC (1:5000, ABCAM cat#AB32072), C-MYC 323 acetylation 
(1:5000, Millipore cat#ABE27), BRD4 (1:2500, ABCAM cat#AB128874), actin (1:5000, 
Sigma-Aldrich cat#A2228), and α-tubulin (1:5000, Active Motif cat#39528). Membranes 
were tagged with secondary rabbit (goat anti-rabbit HRP purchased from BIO RAD) or mouse 
(goat anti-mouse HRP purchased from BIO RAD). Proteins of interest were detected using 
BIO RAD ECL. Quantifications of western blots were conducted using the ImageJ program. 
Analysis of Histone Proteins by Western Blot  
Cell pellets were lysed in either cold Triton Extraction Buffer (0.5% Triton, 2mM PMSF, 
0.02% NaN3, 10mM sodium butyrate) used for histone acid extraction (ABCAM protocol). 
Lysis buffer and TEB were supplemented with protease inhibitor cocktail (PIC) and 
phosphatase inhibitor cocktail (phospho-stop). Protein extracts were separated by SDS-PAGE 
and transferred onto a polyvinyl difluoride (PVDF) membrane. Membranes were tagged with 
primary antibodies and incubated overnight at 4°C. The following primary antibodies were 
used to detect histone acetylation and methylation marks on H3 subunit: H3K27ac (1:5000, 
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Active Motif cat#39134), H3K9ac (1:5000, Active Motif cat#39917), H3K14ac (1:5000, 
Active Motif cat#39698), H3K9me3 (1:5000, Active Motif cat#39765), H3K27me3 (1:5000, 
Active Motif cat#39155), and H3 total (1:5000, Active Motif cat#39763). The following 
primary antibodies were used to detect histone acetylation marks on H4 subunit: H4K16ac 
(1:5000 Active Motif cat#39167), H4K8ac (1:5000, Active Motif cat#39172), H4 total 
acetylation (1:5000, Active Motif cat#39244), and H4 total (1:5000, Active Motif cat#39244). 
Membranes were tagged with secondary rabbit (goat anti-rabbit HRP purchased from BIO 
RAD) or mouse (goat anti-mouse HRP purchased from BIO RAD). Proteins of interest were 
detected using BIO RAD ECL. Quantifications of western blots were conducted using the 
ImageJ program. 
 
RNA Extraction and RNA sequencing  
QIAshredder was used prior to RNA extraction to homogenize cell lysates and eliminate any 
debris. Total RNA was extracted using RNeasy Mini Kit according to instruction manual. 
Upon RNA extraction, 10 µg of purified extract were treated with DNAse to eliminate any 
potential DNA contamination. Upon DNAse treatment, RNA quality and yield were verified 
with Bioanalyser chips using Agilent RNA 6,000 Nano kit according to manufacturer’s 
instructions. The mRNA libraries were created using TruSEq Stranded mRNA LT using 25 ng 
of mRNA extract. RNA sequencing was performed using HiSeq2500 on “rapid run” mode. 
Gene set enrichment analysis was conducted using the “GSEA – Broad Institute” program 
available online: www.broadinstitute.org/gsea.  
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3. Results  
 
Proscillaridin A affects cell viability in a secondary drug screen on ALL and AML cell 
lines  
 In order to identify the drug inducing the greatest effects on cell viability, we 
performed a secondary drug screen by identifying four candidate drugs from the initial drug 
screen conducted by Raynal and colleagues. Initially, we examined effects of disulfiram (anti-
alcohol abuse), pyrithione zinc (anti-dandruff), digitoxin (cardiac glycoside), and 
proscillaridin A (cardiac glycoside) on REH (non-T, non-B ALL) and Thp-1 (AML) cell lines 
(Fig. 16). The IC50 values after 48 hours for disulfiram, pyrithione zinc, and digitoxin were 45 
nM, 100 nM, and 25 nM in REH and 10 µM, 192 nM, and 50 nM in Thp-1 cell lines, 
respectively (Fig. 16A and B). Surprisingly, the IC50 values for proscillaridin A were 3.4 nM 
and 15.3 nM in REH and Thp-1, respectively (Fig. 16A and B). Because these IC50 values fall 
within the cardiac glycosides’ narrow therapeutic window, we decided to pursue our research 
with proscillaridin A on B- and T-ALL cell lines in order to compare its effects on the two 
main branches of pediatric ALL.  
 
Proscillaridin A decreases histone subunit 3 (H3) acetylation and HAT protein 
expression after treatment in B- and T-ALL cell lines 
 We then explored the possibility of epigenetic effects of proscillaridin A on two 
leukemia cell lines, Nalm-6 (B-ALL) and Molt-4 (T-ALL). To do so, we treated both cell lines 
for 24 – 96 hours with proscillaridin A at clinically relevant concentrations (5 nM). In both 
cases, we identified significant decreases in histone acetylation levels of the H3 subunit on 
specific lysine residues (Fig. 12A and 17A). In Molt-4 cell lines, H3K9ac levels rapidly 
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decreased after 24 hours to about 50% relative to untreated cells and continued to decrease 
after 72 and 96 hours of treatment (Fig. 12A and C). H3K27ac steadily decreased from 24 
hours, reaching approximately 10% after 96 hours of treatment (Fig. 12A and C). H3K14ac 
was the one least affected after treatment, reaching its lowest acetylation levels after 48 hours 
and increasing slightly at further time points (Fig. 12A and C). Similar effects on histone H3 
acetylation were observed in Nalm-6 cell line after proscillaridin A treatment (Fig. 17A). 
Interestingly, proscillaridin A treatments do not affect acetylation on H4 residues, 
demonstrating a specific target for the H3 subunit in both cell lines (Fig. 12B and 17B). We 
also examined levels of H3 methylation on lysines K9 and K27 and observed no significant 
changes in both cases (Fig. 17C).  
 In order to determine the cause of these reduced histone acetylation levels, we 
investigated enzymes involved in modifying post-translational histone acetylation. We first 
examined HDACs, the family of enzymes involved in removing acetyl groups from histone 
tail residues. After 48 hours of proscillaridin A treatment, we identified no significant changes 
in HDAC protein expression by western blot (Fig. 17D). We then assessed the expression of 
HATs. When testing for TIP60 protein levels, a HAT involved in acetylating both histone 
(H3K14ac and H4) and non-histone proteins, we discovered an overall decrease after 
treatment in both cell lines, even at very short time points (figure 12D) [345].  In Nalm-6, 
levels of TIP60 protein expression begin to decrease after 16 hours, attaining its lowest 
expression after 96 hours of roughly 20% (Fig. 12D and E). In Molt-4, a much more potent 
effect of proscillaridin A treatment is observed; a significant decrease in TIP60 protein levels 
are observed commencing at the 8-hour mark and reaching nearly inexistent levels after 48 – 
96 hours (Fig. 12D and E). We next sought to investigate other HATs involved in H3 subunit 
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acetylation. To do so, we examined CBP, P300, and GCN5 in both cell lines (Fig. 12F and G 
and Fig. 18). We found that CBP decreases significantly to roughly 30% after 48 hours and 
continues to decrease thereafter in Molt-4 after treatment with proscillaridin A (Fig. 12F). In 
addition, P300 also decreases in Molt-4 in a time-dependent manner after treatment, reaching 
approximately 20% of control values after 96 hours of proscillaridin A treatment (Fig. 12G). 
Interestingly, significant changes in CBP and P300 were not observed in Nalm-6 cell line (Fig. 
18A and B). In both cell lines, however, we found that proscillaridin A treatment does not 
alter GCN5 protein levels (Fig. 18C).  
 
Proscillaridin A reduces expression of the C-MYC oncogene in B- and T-ALL cell lines 
 As previous studies have demonstrated, in order for the C-MYC oncogene to 
upregulate target gene expression, it is recruited to acetylated histone tail residues by 
bromodomain proteins [240]. Since there were significant decreases of histone acetylation 
after treatment, we investigated potential changes of gene expression of the C-MYC oncogene 
and BRD4, the bromodomain protein involved in C-MYC recruitment (Fig. 13). We 
discovered a prominent decrease in C-MYC in both Nalm-6 and Molt-4 cell lines (Fig. 13A). 
In Nalm-6, significant deregulation in C-MYC protein expression is observed after 48 hours 
treatment (Fig. 13A). On the other hand, a significant C-MYC reduction in Molt-4 is observed 
even after 16 hours of proscillaridin A treatment and continues to decrease thereafter (Fig. 
13A). When testing protein levels of the BRD4 bromodomain, we determined no change in 
expression in Molt-4, whereas a slight non-significant increase was observed in Nalm-6 (Fig. 
13B).  
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 Lysine acetylation is an important post-translational modification that leads to 
increased C-MYC stability [205, 206, 279]. Our findings demonstrating decreases in TIP60, 
CBP, and P300 – otherwise known as HATs involved in acetylating and stabilizing the C-
MYC oncogene at lysines K143, K157, K275, K317, K323, K371, and K417 – encouraged us 
to investigate C-MYC acetylation levels. By western blot, we discovered a decrease in lysine 
323 acetylation that occurs prior to C-MYC loss in both Nalm-6 and Molt-4 cell lines after 24 
– 96 hours of treatment (Fig. 13C). This interesting finding demonstrates that instability of the 
C-MYC oncogene is produced subsequently to proscillaridin A treatments by decreasing HAT 
expression levels, which can be one potential cause for degradation and diminished oncogenic 
protein function. 
 In order to determine which C-MYC target genes are effectively downregulated, RNA 
sequencing was performed on Molt-4 cell line after 48 hours of proscillaridin A treatment. In 
order to compare untreated control cells to cells treated with proscillaridin A, we performed a 
gene set enrichment analysis (GSEA) on C-MYC target gene data sets. We observed a 
significant decrease of C-MYC target genes after proscillaridin A treatment (Fig. 13D). We 
then classified these genes according to their function and determined that the majority are 
involved in mRNA processing and post-translational regulation of gene expression (Fig. 13E). 
In addition, some C-MYC target genes involved in mTOR and E2F signaling, two oncogenic 
pathways usually found to be upregulated in T-ALL, were also reduced (Fig. 13E). These 
interesting RNA sequencing data show noticeable effects of proscillaridin A not only on the 
C-MYC protein, but also on the cross-talk between C-MYC and other oncogenic pathways 
(Fig. 13E). We then selected five noteworthy genes involved in development and progression 
of certain cancers, including leukemia, that were identified as having significant decreases in 
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normalized read counts (RC) amongst all C-MYC target genes present (Fig. 13F). We 
identified CDC45, a gene involved in cell proliferation [443]. We also identified APEX1, a 
gene involved in single-strand DNA repair [444]. In solid tumors, APEX1 is overexpressed 
and is correlated with cell survival, cell growth, and development of a tumorigenic phenotype 
[444]. In addition to these functions, it is a regulator of Notch1 activity, a pathway oftentimes 
upregulated in pediatric leukemia cases. We also identified RAN, a gene involved in 
activating the PI3K/Akt/mTORC and Ras/MEK/ERK pathways, both playing roles in 
leukemia development and progression [445, 446].  
 
Proscillaridin A downregulates genes involved in oncogenic pathways and upregulates 
genes involved in cellular differentiation  
 We next considered studying effects of proscillaridin A treatment on cell 
differentiation. In order to do so, we first selected all genes upregulated by proscillaridin A by 
one or more standard deviations (Fig. 19A). By doing so, 491 genes were classified as being 
upregulated in our data set. From this gene list, we identified 67 upregulated genes involved in 
cellular differentiation pathways (Fig. 14A). We then considered the top 12 most upregulated 
genes involved in cell differentiation. We discovered that a number of these genes involved in 
T-cell development are upregulated after treatment (Fig. 14A). From this group, we 
discovered two genes involved in T-cell differentiation (SGK1 and BCL6) and five genes 
involved in T-cell activation pathways (DUSP10, LIF, PLK2, FOS, and JUN).  
 Interestingly, two of the most upregulated genes in our RNA sequencing samples were 
FOS and JUN. In most cases, both these genes are associated with oncogenic functions [447]. 
However, in T-cells, they form a protein complex known as AP-1 that plays a role in T cell 
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differentiation and activation when interacting with the NFAT protein family [448-450]. 
Because FOS and JUN are the second and third most upregulated differentiation genes in our 
samples, respectively, we believe an upregulation of the AP-1 protein complex occurs in 
proscillaridin A treated cells that drives cell differentiation. In addition, proscillaridin A 
upregulates expression of the NF-κB signaling pathway; in T-cells, this pathway interacts with 
and activates AP-1, which can potentially mediate cell differentiation (Fig. 14A) [448]. 
 We next examined genes downregulated after 48 hours of treatment with proscillaridin 
A from our RNA sequencing data. We selected all genes that decreased by two or more 
standard deviations when compared to untreated controls (Fig. 19B). By this means, we 
obtained a total of 612 downregulated genes in our data set. We then classified these genes 
according to protein function (Fig. 14B). We determined that many gene families are 
downregulated, including genes involved in response to interferon-α (IFN- α), cholesterol 
homeostasis, and metabolism. Additionally, we also observed dowregulation of genes 
involved in the mTOR and E2F signaling pathways (Fig. 14B). When investigating oncogenic 
pathways by GSEA, we compared untreated controls to cells treated with proscillaridin A and 
determined that both the mTOR and E2F signaling pathways were in fact downregulated in all 
our samples (Fig. 14C and D). Hence, we concluded that proscillaridin A does not only target 
the C-MYC oncogene and its target genes, it also affects other signaling pathways that are 
present in T-ALL patients.  
 We then sought to determine specific genes downregulated in each of these oncogenic 
pathways identified. Among the E2F targets, we discovered five genes that play a role in 
leukemia development and progression that are shown to have significantly lower normalized 
read counts after treatment (Fig. 14C). These genes play a role in increasing cell proliferation 
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(MCM7) and inhibiting normal lymphoid development and cell cycle progression (HMGA1) 
[451]. Other genes include PAICS, shown to be upregulated in relapse cases, and MYBL2, a 
protein that interacts with micro-RNAs in AML cases leading to formation of a malignant 
phenotype [105, 452]. Among all mTOR target genes, we detected three of which were 
particularly interesting (Fig. 14D). For instance, MCM2, a gene upregulated in relapsed or 
refractory ALL cases, and XBP1, a gene involved in maintaining leukemic cell survival, were 
both found to have decreased RC values after treatment [453, 454]. The fact that multiple 
oncogenic pathways are inhibited after proscillaridin A treatment prompted us to investigate 
tumor suppressor genes. Among the 491 genes upregulated by one or more standard 
deviations, we discovered a significant increase in the normalized read counts for two tumor 
suppressor genes, PTEN and CDKN1a, after proscillaridin A treatment (Fig. 14E) [455, 456]. 
All in all, we concluded that proscillaridin A has a dual role in upregulating cell differentiation 
while downregulating oncogenic signaling pathways involved in development and progression 
of T-ALL. 
 
Clinically relevant concentrations of proscillaridin A induced growth inhibition and cell 
cycle arrest in Nalm-6 and Molt-4 cell lines   
 Next, we examined upregulation of genes induced by proscillaridin A treatment. To do 
so, we selected all genes that increased by two or more standard deviations from our RNA 
sequencing data when compared to untreated controls (Fig. 19B). We then classified genes 
from this set depending on their functions (Fig. 15A). We noticed that genes involved in TGF-
β signaling, an important pathway involved in T-cell differentiation, were upregulated after 
proscillaridin A treatment (Fig. 15A) [457]. In addition, we discovered that genes involved in 
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the P53 pathway and TNF-α signaling via NF-κB are the ones most upregulated after 
treatment (Fig. 15A). The NF-κB signaling pathway is involved in many cell-regulating 
mechanism such as proliferation, survival, and apoptosis. We believe that in this case, 
upregulation of NF-κB is involved in inducing apoptosis. Conversely, to test this hypothesis, 
we performed GSEA on all genes that were differentially expressed upon proscillaridin A 
treatment. We found that genes involved in apoptosis and NF-κB signaling were upregulated 
after treatment, suggesting that NF-κB signaling may be mediating cell death (Fig. 15B). 
Interestingly, we also found that genes involved in oxidative phosphorylation were decreased, 
implying a change in cellular energy pathways that may cause cells to produce less ATP and 
stop growing (Fig. 15B).   
 In order to determine the cytotoxic effects of proscillaridin A treatment in Nalm-6 and 
Molt-4, we first determined IC50 values after 48 hours of treatment. To do so, we treated both 
cell lines with different concentrations of proscillaridin A ranging from 0.5 nM to 100 nM. We 
discovered IC50 values of 3.0 nM and 2.3 nM in Nalm-6 and Molt-4, respectively (Fig. 15C). 
Most importantly, these concentrations of proscillaridin A fall into the clinical range, which is 
approximately 1 – 10 nM in human patients. By flow cytometry, we determined a block in the 
cell cycle in the G2/M phase (Fig. 15D and E). In Nalm-6, there are significantly less cells in 
S phase and higher amounts in G2/M phase that was dose dependent (Fig. 15D and E). Since 
Molt-4 cells are more sensitive to proscillaridin A, there was a significantly greater amount of 
apoptosis after 48 hours that was not present in Nalm-6 cell line (Fig. 15D and E). In both 
cases, the optimal dose to induce G2/M block and limiting excessive cytotoxicity is 5 nM (Fig. 
15D and E).  
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Figure 12: Proscillaridin A treatment decreases histone 3 acetylation levels and 
expression of HATs in Molt-4 and Nalm-6 leukemic cell lines. 
A. Western blot depicting decreases in histone 3 lysine residue acetylation (K9, K14, and 
K27) after 2 – 96 hours of proscillaridin A treatment (5 nM) in Molt-4 cell line.  
B. Western blot depicting histone 4 lysine residue acetylation (K8, K16, and total 
acetylation) after 24, 48, 72, and 96 hours of proscillaridin A treatment (5 nM) in Molt-
4 cell line.  
C. Quantification of histone 3 lysine residue acetylation shown in figure 12A.  
D. Expression of TIP60 after 2 – 96 hours treatment with proscillaridin A (5 nM) in Molt-
4 (top) and Nalm-6 (bottom) cell lines by western blot.  
E. Quantification of TIP60 protein levels, expressed as a percentage, in Molt-4 (black) 
and Nalm-6 (grey) cell lines.  
F. Western blot quantification of CBP in Molt-4 cell line after 4 – 96 hours treatment 
with proscillaridin A (5nM).  
G. Western blot quantification of P300 in Molt-4 cell line after 2 – 96 hours treatment 
with proscillaridin A (5nM).  
 
 
 
  
 90 
 
 
  
C-MYC 
0    2   4    8    16  24  48  72 96  (h) 
Tubulin 
A Pros. 5nM B 
Actin 
BRD4 
 0       V      24    48     72    96   (h) 
Pros. 5nM 
C-MYC 
K 323ac 
Actin 
CTL      24       48       72       96   (h) 
Pros. 5nM 
C-MYC 
K 323ac 
Actin 
C 
Actin 
BRD4 
M
ol
t-4
 
N
al
m
-6
 
C-MYC 
Tubulin 
M
ol
t-4
 
N
al
m
-6
 
M
ol
t-4
 
N
al
m
-6
 
D C-MYC target genes V.1 
E 
F 
Min 
Max 
C-MYC Target Genes 
R
C
 (1
03
) 
   
 91 
Figure 13: Proscillaridin A treatment decreases expression of the C-MYC oncogene and 
C-MYC target genes in Nalm-6 and Molt-4 leukemic cell lines. 
A. Western blot depicting expression of the C-MYC oncogene after proscillaridin A 
treatment (5 nM) after 2 – 96 hours in Molt-4 (top) and Nalm-6 (bottom) cell lines.  
B. Western blot depicting expression of BRD4 after proscillaridin A treatment (5 nM) 
after 2 – 96 hours in Molt-4 (top) and Nalm-6 (bottom) cell lines.  
C. Western blot depicting C-MYC and C-MYC acetylation on lysine 323 in Molt-4 (top) 
and Nalm-6 (bottom) cell lines after 24 – 96 hours of treatment.  
D. RNA sequencing data depicting gene expression data sets of C-MYC target genes after 
48 hours treatment with 5 nM of proscillaridin A in Molt-4 cell line. The red color 
indicates untreated cells while the blue color indicates treated cells. Each black vertical 
line is a gene in the list.    
E. RNA sequencing data on genes obtained from the C-MYC oncogene data set classified 
according to gene function in Molt-4 cell line.   
F. RNA sequencing analysis depicting selected C-MYC target genes significantly 
decreased after proscillaridin A treatment (5 nM) expressed as the number of read 
counts (RC). 
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Figure 14: Proscillaridin A downregulates genes involved in oncogenic pathways while 
upregulating genes involved in cellular differentiation. 
A. Left: Heat map depicting all genes involved in cellular differentiation that are 
upregulated after 48 hours of proscillaridin A (5 nM) treatment. A total of 67 genes 
were identified as being upregulated after treatment. Genes used in this analysis were 
obtained by taking all upregulated genes from 1 standard deviation above the mean. 
Right: Heat map depicting the top 12 most upregulated genes taken from the 67 genes 
mentioned in the right panel of figure 14A.  
B. All genes downregulated by two or more standard deviations below the mean from 
RNA sequencing data classified according to gene function. Genes with the smallest p-
value are correlated to the most expressed gene functions in our data set. A total of 612 
downregulated genes were identified.   
C. Left: Gene set enrichment analysis of all genes in our dataset comparing untreated 
control cells to 48 hours proscillaridin A (5 nM) treated cells. The E2F oncogenic 
pathway is shown to be downregulated in proscillaridin A treated cells compared to 
untreated controls. Right: Histogram depicting selected E2F target genes from RNA 
sequencing data which are significantly decreased after proscillaridin A treatment (5 
nM) expressed as the number of read counts (RC). 
D. Left: Gene set enrichment analysis of all genes in our dataset comparing untreated 
control cells to 48 hours proscillaridin A (5 nM) treated cells. The mTOR oncogenic 
pathway is shown to be downregulated in proscillaridin A treated cells compared to 
untreated controls. Right: Histogram depicting selected mTOR target genes from RNA 
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sequencing data which are significantly decreased after proscillaridin A treatment (5 
nM) expressed as the number of read counts (RC). 
E. RNA sequencing analysis depicting tumor suppressor genes significantly upregulated 
after proscillaridin A treatment expressed as the number of read counts (RC).  
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Figure 15: Proscillaridin A induces growth inhibition and cell cycle arrest in Nalm-6 and 
Molt-4 leukemic cell lines. 
A. All genes upregulated by two or more standard deviations above the mean from RNA 
sequencing data classified according to gene function. Genes with the smallest p-value 
are correlated to the most expressed gene functions in our data. A total of 189 
downregulated genes were identified.  
B. Gene set enrichment analysis of all genes in our data set comparing untreated control 
cells to 48 hours proscillaridin A (5 nM) treated cells. Genes involved in the NF-κB 
signaling pathway and apoptosis were shown to be significantly upregulated after 
treatment, whereas genes involved in oxidative phosphorylation were found to be 
significantly downregulated.  
C. Molt-4 (black) and Nalm-6 (grey) cell lines treated for 48 hours with proscillaridin A 
(0.5nM – 100nM). IC50 values are 2.3 nM and 3.0 nM for Molt-4 and Nalm-6 and 
Molt-4, respectively. (n=3).  
D. Quantification of cell cycle arrest in Nalm-6 (top) and Molt-4 (bottom) cell lines. Cells 
were treated for 48 hours with 2.5nM, 5nM, and 7.5nM of proscillaridin A Two-way 
ANOVA was performed to determine significant values. Statistical analysis was 
performed using two-way ANOVA with p≤0.05 (n=3). 
E. Cell cycle analysis by flow cytometry by BrdU staining in Molt-4 (top) and Nalm-6 
(bottom) cell lines. Cells were treated 48 hours with 5nM of proscillaridin A.  
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Figure 16: Secondary drug screen on ALL and AML cell lines. (Supplementary figure 1). 
A. REH cells were treated for 24 (red curve) and 48 (blue curve) hours with different 
concentrations of disulfiram, pyrithione zinc, digitoxin, and proscillaridin A to identify 
an IC50 value for each drug. Lowest IC50 was identified in proscillaridin A.  
B. Thp-1 cells were treated for 24 (red curve) and 48 (blue curve) hours with different 
concentrations of disulfiram, pyrithione zinc, digitoxin, and proscillaridin A to identify 
an IC50 value for each drug. Lowest IC50 was identified in proscillaridin A. 
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Figure 17: Proscillaridin A induces epigenetic effects in Molt-4 and Nalm-6 cell lines. 
(Supplementary figure 2). 
A. Histone 3 lysine residue acetylation (K9, K14, and K27) after 24, 48, 72, and 96 hours 
of proscillaridin A treatment in Nalm-6 cell line. Vorinostat (V) used as a positive 
control for acetylation.  
B. Histone 4 lysine residue acetylation (K8, K16, and total acetylation) after 24, 48, 72, 
and 96 hours of proscillaridin A treatment in Nalm-6 cell line. Expression of H4 
subunit acetylation was not significant.  
C. Western blot quantification of histone 3 lysine residue methylation (9 and 27) after 24, 
48, 72, and 96 hours of proscillaridin A treatment in Molt-4 (right) and Nalm-6 (left) 
cell lines.  
D. Western blot quantification of HDAC1, HDAC2, and HDAC4 protein expression 
levels, expressed as a percentage, in Molt-4 (left) and Nalm-6 (right) cell lines. 
Changes in protein expression levels were not significant.  
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Figure 18: Expression of P300, CBP, and GCN5 HATs remain stable after proscillaridin 
A treatmentin Nalm-6 and Molt-4 cell lines. (Supplementary figure 3). 
A. Western blot quantification of P300 levels after 2h – 96h treatment with proscillaridin 
A (5 nM) in Nalm-6 cell line.  
B. Western blot quantification of CBP levels after 2h – 96h treatment with proscillaridin 
A (5 nM) in Nalm-6 cell line.  
C. Western blot quantification of GCN5 levels after 24h – 96h treatment with 
proscillaridin A (5 nM) in Molt-4 (black) and Nalm-6 (grey) cell lines.  
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Figure 19: Proscillaridin A treatment induces changes in gene expression in Molt-4 cell 
line. (Supplemental figure 4). 
A. Graph depicting changes in gene expression analyzed by RNA sequencing. Blue lines 
indicate one standard deviation above the mean for upregulated genes and one standard 
deviation below the mean for downregulated genes.  
B. Graph depicting changes in gene expression analyzed by RNA sequencing. Blue lines 
indicate two standard deviation above the mean for upregulated genes and two 
standard deviations below the mean for downregulated genes.  
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4. Discussion 
  
 Despite recent treatment advances and generally high cure rates, ALL remains the 
leading cause of death by disease in children. In order to treat pediatric leukemia, patients 
must receive extremely high doses of chemotherapy drugs to attain remission before the 
eventual cure. These toxic compounds produce many short and long-term side effects that are 
detrimental for the patient such as toxicity, fertility issues, secondary cancers, and 
neurocognitive disorders [11, 36, 458, 459]. Hence, the need to develop less toxic drugs is 
evident. In addition, patients experiencing relapsed or resistant ALL are characterized as 
having a very poor prognosis. Epigenetic deregulation, including DNA methylation and post-
translational histone modifications, is an important player in development of relapsed or 
resistant leukemia. These epigenetic modifications are reversible chemical reactions; hence, by 
targeting these deregulated epigenetic marks, we can induce cancer cell differentiation and 
ultimately cell death.  
 Here, we demonstrate that repositioning the cardiac glycoside proscillaridin A has 
substantial epigenetic and anticancerous properties in pediatric leukemia cell lines. We 
observed a significant decrease in histone acetylation correlated with decreases of three HATs 
(TIP60, CBP, and P300). In addition, we observed a significant decrease in C-MYC oncogene 
protein levels and its target genes. Interestingly, we determined a decrease in C-MYC 
acetylation, a post-translational modification involved in stabilizing the C-MYC oncogene and 
preventing its degradation. In addition to targeting the C-MYC oncogenic pathway, 
proscillaridin A also affects mTOR and E2F signaling, two additional pathways involved in 
development and progression of leukemia. Moreover, proscillaridin A upregulates genes 
involved in T-cell differentiation and activation. When testing effects of clinically relevant 
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concentrations of proscillaridin A on cell viability, we observed an upregulation of genes 
involved in apoptosis as well as cell cycle block at the G2/M phase.  
 One of the most frequently upregulated oncogenes in pediatric ALL, and human 
cancers in general, is C-MYC. In normal cells, C-MYC expression is very tightly controlled; 
in tumor cells, however, regulatory mechanisms are dysfunctional [211, 218]. Furthermore, 
changes in either post-translational modifications favoring C-MYC protein stability or 
increases in protein expression levels enabling cells to proliferate at very high rates [201]. In 
other cases, constitutive C-MYC expression is due to activation mutations, genetic 
amplifications, or chromosomal translocations [201, 218-221]. In order for C-MYC to 
upregulate expression of its target genes, it is recruited to acetylated histone tail residues by 
the bromodomain protein family, dimerizes with MAX, and forms a complex to initiate 
transcription. In normal cells, expression of the C-MYC master regulator is controlled mainly 
by post-translational modifications like ubiquitination, acetylation, and phosphorylation of 
specific residues on the protein. Some of these modifications induce low protein half-life or 
stability, while others have an opposite effect. In cancer cells, these regulatory mechanisms are 
deregulated, ultimately leading to increases in C-MYC expression and stability [205, 206]. For 
example, acetylation of seven different lysine residues (K143, K157, K275, K317, K323, 
K371, and K417) directed by HATs such as TIP60, CBP, P300, and GCN5, are known to 
stabilize the protein and prevent its degradation in cancer cells. Two of these residues, lysines 
K323 and K417, are ubiquitination sites as well that, when present, direct C-MYC to 
proteasomal degradation. When these residues are acetylated, they prevent ubiquitin 
attachment. Hence, the observed decrease of lysine K323 acetylation induced by proscillaridin 
A can potentially liberate this specific site so a ubiquitin moiety can be linked.    
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 In recent years, many researchers have tried to target C-MYC therapeutically. 
However, the lack of an active site or ligand-binding domain has prevented the development 
of novel therapeutic inhibitors. Hence, some groups have tried targeting the bromodomain 
proteins involved in C-MYC recruitment as a means to decrease C-MYC target gene effects 
[237, 238]. There are three members of the bromodomain and extra-terminal (BET) family 
that associate with C-MYC recruitment, termed BRD2, BRD3, and BRD4, with the latter 
being the most pertinent in terms of C-MYC association and activation [207, 239]. The link 
between BET proteins and C-MYC recruitment prompted the development of JQ1, the first 
selective BET inhibitor (BETi), which blocks C-MYC recruitment onto BRD4 and ultimately 
blocks both C-MYC and C-MYC target gene transcription [240]. In fact, numerous completed 
or ongoing clinical trials are studying the effects of these BETi on a variety of human cancers, 
including acute leukemia (NCT02543879, NCT01949883, NCT02157636, and 
NCT01987362).  
 Despite all these promising results, there has been proof that BETi are not as efficient 
as initially thought out to be. Recently, studies have shown that some cells either do not 
respond to JQ1 or develop resistance to treatment [106, 242, 247]. For instance, Ott and 
colleagues demonstrated that mice treated with JQ1 eventually die of leukemia and that upon 
analysis of these mice, there is an upregulation of the C-MYC protein [239]. In another study, 
Rathert and colleagues determined that upon JQ1 treatment, AML cell lines and patient 
samples overexpress WNT signaling genes that confer resistance to treatment.  
 One way to develop new drugs for treating pediatric ALL is by drug repositioning 
FDA-approved molecules. In order to avoid the lengthy and costly process, drug repositioning 
– also known as drug repurposing – can be conducted to develop new anticancer therapies 
 108 
[395, 396]. This process consists of using drugs that are already approved by the FDA for one 
indication in order to treat other disease types, such as cancer [395, 396]. Because drug 
repositioning uses approved FDA drugs that have a long history of preclinical and 
toxicological studies, they can quickly be developed or incorporated into treating cancer 
without passing through rigorous testing [395, 396]. The primary benefits in screening and 
repositioning these FDA-approved molecules include much lower cost and reduced side-
effects compared to cytotoxic therapies currently used [395].  
 Cardiac glycosides are naturally occurring compounds that can be separated into two 
main groups: bufadienolides and cardenolides. Both cardiac glycoside families share a similar 
molecular structure and function as sodium-potassium (Na+/K+) channel blockers, leading to 
increases in intracellular sodium levels. These variations in intracellular sodium levels 
decrease activity of the sodium-calcium (Na+/Ca2+) pump, thereby leading to increases in 
calcium levels and cardiac contractility in patients suffering from arrhythmias and congestive 
heart failure [400, 401, 403]. Interestingly, cardiac glycoside intake has been previously 
correlated to anti-cancerous properties. It has been revealed that patients taking cardiac 
glycosides during or prior to chemotherapy not only have less invasive cancers, but also 
present a decreased mortality risk after induction phase therapy is completed [404-407]. In 
fact, epidemiological studies have demonstrated a decreased risk in developing leukemia in 
patients who are treated with cardiac glycosides, while other studies demonstrate a synergy 
between cardiac glycosides and some cytotoxic chemotherapy drugs [408, 409, 412]. 
Although the exact anticancerous mechanism elicited by cardiac glycosides is unknown, a few 
potential speculated mechanisms are currently being investigated. For instance, some groups 
believe that cardiac glycosides upregulate important tumor suppressor genes and genes 
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involved in apoptosis, while others believe that energy-producing pathways like oxidative 
phosphorylation and glycolysis are targeted [423-430]. Regardless, the overall beneficial 
effects on cancer treatment has encouraged some research groups to investigate cardiac 
glycosides repositioning in treating cancer patients (NCT00837239, NCT01887288, 
NCT02106845).  
 All in all, we demonstrate that proscilaridin A acts as an epigenetic drug on ALL cell 
lines inducing potent gene expression reprogramming. Proscillaridin A targets both C-MYC 
protein levels and histone acetylation levels, which may in part decrease binding of C-MYC to 
acetylated DNA residues. More studies are required to fully study the mechanism of action of 
proscillaridin A and to discover drug combinations to produce synergistic responses for further 
clinical trials. 
 Chapter 3: Discussion and Future Considerations 
 
 In order to treat pediatric leukemia, patients must receive extremely high doses of 
chemotherapy drugs to attain remission before the eventual cure. These toxic compounds 
produce many short and long-term side effects that are detrimental for the patient such as 
toxicity, fertility issues, secondary cancers, and neurocognitive disorders [11, 36, 458, 459]. 
Hence, the necessity to develop new cancer medication is evident. The best means to attain 
higher remission rates, counter treatment resistance, and decrease long-term side effects, is by 
combining different types of therapies together.  
 By introducing epigenetic drugs into chemotherapy regimens, we hope to accomplish 
two very important things. First, the addition of epigenetic drugs can potentially sensitize 
cancer cells to chemotherapy drugs by decreasing the apoptotic threshold [248]. Subsequently, 
by inducing epigenetic reprogramming, epigenetic drugs are able to alter gene expression in 
cancer cells making them more sensitive to lower doses of cytotoxic therapies [248]. 
Moreover, these consequences may also decrease severe side effects of treatment. Second, it 
has been widely proven that cancer cells are addicted to epigenetic marks; they become 
dependent on these epigenetic modifications for their survival, drug resistance, and 
maintenance of a malignant phenotype [357, 358, 460]. Since epigenetics governs gene 
expression, cancer cells rely on their epigenomes to express certain proteins while repressing 
others [357, 358, 460]. By treating patients with drugs inducing epigenetic changes, we are 
able to target proteins involved in proliferation and cell survival, while simultaneously 
activating differentiation and apoptosis. 
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 By screening FDA-approved drugs, we can identify possible candidates in order to 
reposition them to treat many types of cancers. As demonstrated by Raynal and colleagues in 
their drug screen, many FDA-approved compounds have unsuspected epigenetic and 
anticancerous properties [399]. In our study, we tested four of these FDA-approved drugs 
identified (disulfiram, pyrithione zinc, digitoxin, and proscillaridin A) in pediatric ALL and 
AML cell lines. We discovered that proscillaridin A, a cardiac glycoside that has been 
administered to patients for over 40 years, induced the most prominent epigenetic and 
anticancerous characteristics and decided to pursue our research project with this drug. Drug 
repositioning has many positive points. For instance, previously acquired knowledge on side 
effects, clinically administered doses, and plasma levels of the given medication are all known 
due to a large amount of previous preclinical and clinical tests. Additionally, studies on 
toxicology, pharmacokinetics, and pharmacodynamics have already been thoroughly 
reviewed. These aspects of repositioning enable drugs to pass rapidly into preclinical and 
clinical testing.  
 Here, we explain the efficacy of repositioning the cardiac glycoside proscillaridin A in 
B- and T-ALL cell lines. We demonstrate that proscillaridin A targets the C-MYC oncogene 
in pediatric ALL cell lines and decreases histone acetylation levels that are required for C-
MYC recruitment and transcriptional activation of its target genes. The fact that proscillaridin 
A treatment induces downregulation in HAT enzymes TIP60, P300, and CBP is important for 
two main reasons. First, it explains the decreases in H3 subunit acetylation levels. Second and 
most importantly, it explains decreases in C-MYC acetylation levels that occur prior to C-
MYC degradation. All three aforementioned HAT enzymes are involved in post-translational 
acetylation of the C-MYC oncogene, consequently stabilizing it and preventing its 
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degradation. Hence, decreases of C-MYC acetylation levels correlated to decreases in TIP60, 
P300, and CBP enzymes induce formation of an unstable protein with a very low half-life. By 
targeting both histone and C-MYC acetylation levels, proscillaridin A is able to directly and 
indirectly inhibit C-MYC functions by an epigenetic mechanism. For these reasons, we 
believe that proscillaridin A can potentially be developed to treat pediatric cancer patients in 
combination with either low dose of cytotoxic therapy or an FDA-approved epigenetic DNA 
demethylating agent like decitabine. Interestingly, our RNA sequencing data on the T-ALL 
cell line Molt-4 demonstrate the ability for proscillaridin A to target multiple oncogenic 
pathways oftentimes upregulated in T-ALL, as demonstrated by a decrease in C-MYC, 
mTOR, and E2F signaling. Finally, induction of selected T-cell differentiation genes occurs 
after 48 hours treatment, further demonstrating the positive role of proscillaridin A on T-ALL 
cells.  
 The mechanism of action of proscillaridin A on pediatric B- and T-ALL cell lines has 
not yet been fully characterized. Raynal and colleagues demonstrated that proscillaridin A and 
other members of the cardiac glycoside family modulate changes of intracellular calcium 
levels in their colon cancer cell model [399]. We believe that these increases of intracellular 
calcium levels also occur in pediatric ALL cell lines, which in turn induce downstream effects 
on histone acetylation levels, expression of HATs, and the C-MYC oncogene. In their study, 
Raynal and colleagues demonstrated the importance and necessity of calcium/calmodulin-
dependent protein kinase (CamK) activation after proscillaridin A treatment. Their study also 
showed the importance of the Orai calcium channel in triggering the downstream calcium 
pathway affecting CamK [399]. When calcium levels in the endoplasmic reticulum are low, an 
interaction between stromal interaction molecule 1 and 2 (STIM1/2) and the selective calcium 
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channels Orai1/2/3 is formed, causing an influx of calcium ions from the outside of the cell 
into the cytoplasm [399, 461]. This phenomenon is termed store-operated calcium entry 
(SOCE). Based on their results, we believe a relationship between the Orai channels and 
activation of downstream calcium signaling pathways mediates the proscillaridin A 
mechanism. In order to test our hypothesis, we would first need to knock out CamK or 
calmodulin by shRNA or CRISPR/Cas9 and determine if decreases in cell viability, histone 
acetylation, HATs, and C-MYC are still observed. If no changes are observed compared to 
untreated controls (phenotype rescue), then proscillaridin A requires calcium signaling in 
order to accomplish its anticancerous and epigenetic properties. Additionally, we plan on 
conducting either an shRNA or CRISPR/Cas9 knock out of CBP and/or TIP60 to determine 
whether decreases of cell viability and C-MYC levels are results of those two enzymes.  
 In addition, although our RNA sequencing data demonstrate upregulation of certain T-
cell differentiation genes after 48 hours, we believe that additional genes involved in cell 
differentiation and activation will be upregulated as a consequence following long-term 
treatment of 96 hours or more. To test for long-term differentiation marks, we believe treating 
for 96 hours, followed by 48 hours incubation in drug-free medium, will upregulate genes 
involved in B- or T-cell receptor formation and cell surface markers like CD24 and CD34 for 
T-cells and CD19 and CD25 for B-cells [462, 463].  
 Finally, we believe that C-MYC decreases are a consequence of ubiquitin mediated 
proteasomal degradation. Poly-ubiquitination is an important post-translational modification 
that regulates expression of C-MYC in normal cells. We believe a link exists between 
increases of intracellular calcium levels and ubiquitination of the C-MYC protein; however, 
we have yet to obtain concrete evidence linking the two pathways. To test this hypothesis, we 
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can perform two experiments. First, we can conduct an immunoprecipitation of C-MYC to 
probe for ubiquitination. Another way to test whether C-MYC is ubiquitinated and sent to the 
proteasome for degradation is by treating cells with proscillaridin A in combination with the 
proteasomal inhibitor MG-132. If cell growth and C-MYC protein levels are rescued after 
combination treatment, then C-MYC is degraded by the proteasome in proscillaridin A treated 
cells. Furthermore, in order to confirm the observed decreases of C-MYC acetylation after 
treatment, we plan on conducting a mass spectrometry for post-translational acetylation on 
lysines K143, K157, K275, K317, K323, K371, and K417 shown to stabilize the C-MYC 
protein [206, 279].  
 The ability for proscillaridin A to induce epigenetic and anticancerous effects on acute 
leukemia cell lines raises the question as to whether it will have similar effects on other cancer 
cell lines as well. Thus, investigating effects of proscillaridin A in drug repositioning studies 
can potentially aid us in evaluating its effects that are either specific for leukemia cell lines, or 
might be a general mechanism in which it can induce epigenetic and anticancerous effects. So 
far, we have obtained similar results in pediatric sarcoma, but not pediatric neuroblastoma, cell 
lines tested thus far, suggesting that proscillaridin A treatments might only work on selected 
pediatric cancers. Unfortunately, the reason as to why proscillaridin A has greater effects on 
certain cancers compared to others has not yet been determined. Further tests on additional 
pediatric cancer cell lines should be conducted in future studies in order to test its potency in 
other liquid or solid malignancies.  
 Using any drug as a monotherapy is not the right approach when treating any types of 
cancers. Hence, we would like to study effects of combining proscillaridin A, a histone-
targeting drug, to DNA demethylating agents like decitabine for the following two reasons. 
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Firstly, targeting both histones and DNA methylation levels can potentially lead to synergistic 
drug interactions that might involve additional upregulation of tumor suppressor genes and 
differentiation pathways compared to decitabine or proscillaridin A monotherapies. Secondly, 
because a cancer cell is addicted to its epigenetic modifications, targeting both histone and 
DNA epigenetics can potentially reverse a cancerous phenotype by triggering growth arrest 
and cell differentiation. Many people believe administration of drugs inducing epigenetic 
changes cause a systemic effect, but that is not necessarily true; cancer cells depend on their 
epigenomes for their survival whereas normal cells do not. Hence, when a drug induces 
epigenetic reprogramming, a normal cell is able to adapt to these changes whereas a cancerous 
cell cannot. This event forces the cancerous cell to change it behavior, which can potentially 
trigger apoptosis, senescence, or even differentiation. After completing these necessary 
experiments, our next step is to validate these results in vivo. We would need to inject non-
obese diabetic/severe combined immunodeficiency (NOD/SCID) mice with either Nalm-6 or 
Molt-4 cells, wait for leukemic engraftment, and treat these mice with vehicle, proscillaridin A 
alone, decitabine alone, or proscillaridin A in combination with decitabine. We would then 
analyze overall mouse survival, spleen morphology, and blast counts in the bone marrows and 
blood streams. All in all, results that we have obtained to date are very promising in terms of 
anticancerous properties of proscillaridin A. We will continue to investigate this candidate 
drug in the future in hopes of eventually administering proscillaridin A in clinical trials.  
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Annexes I: Permission to use figures  
 
 
Permission to use figure 5: The three classes of epigenetic modifications.  
 
 
 
 
Permission to use figure 6: Examples of epigenetic readers, writers, and erasers.  
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Permission to use figure 7: Differences in DNA methylation levels between normal and 
cancerous tissues.  
 
 
 
 
 
 
 
 
Permission to use figure 8: DNA and nucleosomes.  
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Permission to use figure 9: Histone tail modifications.  
 
 
 
 
 
Figure 10: Structure of the human C-MYC oncogene 
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Permission to use figure 11: Molecular structure of proscillaridin A:  
 
 
 
  
 
